JP2022510430A - モルホリニル、ピペラジニル、オキサゼパニル及びジアゼパニルo-糖タンパク質-2-アセトアミド-2-デオキシ-3-d-グルコピラノシダーゼ阻害剤 - Google Patents
モルホリニル、ピペラジニル、オキサゼパニル及びジアゼパニルo-糖タンパク質-2-アセトアミド-2-デオキシ-3-d-グルコピラノシダーゼ阻害剤 Download PDFInfo
- Publication number
- JP2022510430A JP2022510430A JP2021531906A JP2021531906A JP2022510430A JP 2022510430 A JP2022510430 A JP 2022510430A JP 2021531906 A JP2021531906 A JP 2021531906A JP 2021531906 A JP2021531906 A JP 2021531906A JP 2022510430 A JP2022510430 A JP 2022510430A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- acetamide
- thiazole
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 title description 3
- 125000004193 piperazinyl group Chemical group 0.000 title description 2
- 125000005959 diazepanyl group Chemical group 0.000 title 1
- 125000005961 oxazepanyl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 243
- 238000000034 method Methods 0.000 claims abstract description 90
- 150000003839 salts Chemical class 0.000 claims abstract description 87
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 55
- 201000010099 disease Diseases 0.000 claims description 48
- 125000005843 halogen group Chemical group 0.000 claims description 44
- 206010012289 Dementia Diseases 0.000 claims description 31
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 102100030122 Protein O-GlcNAcase Human genes 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 16
- 208000010877 cognitive disease Diseases 0.000 claims description 16
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 15
- 125000004970 halomethyl group Chemical group 0.000 claims description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 15
- 208000024827 Alzheimer disease Diseases 0.000 claims description 14
- 108010045982 hexosaminidase C Proteins 0.000 claims description 14
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 13
- 206010034010 Parkinsonism Diseases 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 11
- 210000004556 brain Anatomy 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 10
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 230000006951 hyperphosphorylation Effects 0.000 claims description 8
- 201000010901 lateral sclerosis Diseases 0.000 claims description 8
- 208000005264 motor neuron disease Diseases 0.000 claims description 8
- 230000003387 muscular Effects 0.000 claims description 8
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 208000034799 Tauopathies Diseases 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 208000028698 Cognitive impairment Diseases 0.000 claims description 6
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 208000023697 ABri amyloidosis Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 206010018341 Gliosis Diseases 0.000 claims description 3
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims description 3
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 3
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 3
- 208000024777 Prion disease Diseases 0.000 claims description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 3
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 3
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 238000009825 accumulation Methods 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 230000001054 cortical effect Effects 0.000 claims description 3
- 208000017004 dementia pugilistica Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 206010014599 encephalitis Diseases 0.000 claims description 3
- 230000007387 gliosis Effects 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 125000005347 halocycloalkyl group Chemical group 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 231100000518 lethal Toxicity 0.000 claims description 3
- 230000001665 lethal effect Effects 0.000 claims description 3
- 210000004940 nucleus Anatomy 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 239000004332 silver Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 230000002123 temporal effect Effects 0.000 claims description 3
- 208000017227 ADan amyloidosis Diseases 0.000 claims description 2
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 2
- 208000004434 Calcinosis Diseases 0.000 claims description 2
- 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 230000002308 calcification Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 2
- 208000024571 Pick disease Diseases 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 238000010586 diagram Methods 0.000 abstract 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 137
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 102
- 239000000203 mixture Substances 0.000 description 92
- -1 (2S, 5S) -5-(((2,6-dimethylpyridin-4-yl) oxy) methyl) -2,4-dimethylpiperazine-1-yl Chemical group 0.000 description 89
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 77
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 67
- 239000000543 intermediate Substances 0.000 description 66
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 60
- 238000005481 NMR spectroscopy Methods 0.000 description 60
- 239000002904 solvent Substances 0.000 description 45
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 42
- 239000000243 solution Substances 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- LAPWQPYYMGKHNZ-UHFFFAOYSA-N n-[5-(chloromethyl)-1,3-thiazol-2-yl]acetamide Chemical compound CC(=O)NC1=NC=C(CCl)S1 LAPWQPYYMGKHNZ-UHFFFAOYSA-N 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 35
- 235000019439 ethyl acetate Nutrition 0.000 description 32
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 28
- 238000010828 elution Methods 0.000 description 24
- 0 *C(*)(C(C1)OC*CN1C(*)(*)c1c(*)nc(N(*)C(*)=O)[s]1)[Al] Chemical compound *C(*)(C(C1)OC*CN1C(*)(*)c1c(*)nc(N(*)C(*)=O)[s]1)[Al] 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 238000010898 silica gel chromatography Methods 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- 125000005997 bromomethyl group Chemical group 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 15
- STUHQDIOZQUPGP-UHFFFAOYSA-N morpholin-4-ium-4-carboxylate Chemical compound OC(=O)N1CCOCC1 STUHQDIOZQUPGP-UHFFFAOYSA-N 0.000 description 15
- RIXVESSVKLKKFV-UHFFFAOYSA-N piperazine-1,4-dicarboxylic acid Chemical compound OC(=O)N1CCN(C(O)=O)CC1 RIXVESSVKLKKFV-UHFFFAOYSA-N 0.000 description 15
- ANSMRNCOBLTNBO-UHFFFAOYSA-N 2-bromo-5-fluoropyrimidine Chemical compound FC1=CN=C(Br)N=C1 ANSMRNCOBLTNBO-UHFFFAOYSA-N 0.000 description 14
- ZWOQHSZKILPKKA-MIXAKNBRSA-N s-[2-[3-[[(2r)-4-[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] (2s)-2-[4-(2-methylpropyl)phenyl]propanethioate Chemical compound C1=CC(CC(C)C)=CC=C1[C@H](C)C(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](OP(O)(O)=O)[C@@H](O)[C@H](N2C3=NC=NC(N)=C3N=C2)O1 ZWOQHSZKILPKKA-MIXAKNBRSA-N 0.000 description 14
- 239000011734 sodium Substances 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000012267 brine Substances 0.000 description 13
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 13
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 12
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 12
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 12
- 125000001072 heteroaryl group Chemical group 0.000 description 12
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 9
- 239000003208 petroleum Substances 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- YFTGMMXMLPTTAY-UHFFFAOYSA-N 4-bromo-2-methoxypyridine Chemical compound COC1=CC(Br)=CC=N1 YFTGMMXMLPTTAY-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- 101001120790 Caenorhabditis elegans UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase Proteins 0.000 description 7
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- CDINMPJUENPBKF-UHFFFAOYSA-N bromomethyl morpholine-4-carboxylate Chemical compound BrCOC(=O)N1CCOCC1 CDINMPJUENPBKF-UHFFFAOYSA-N 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- VTRFAYHJKSKHGY-UHFFFAOYSA-N 4-bromo-2,6-dimethylpyridine Chemical compound CC1=CC(Br)=CC(C)=N1 VTRFAYHJKSKHGY-UHFFFAOYSA-N 0.000 description 5
- OFKWIQJLYCKDNY-UHFFFAOYSA-N 5-bromo-2-methylpyridine Chemical compound CC1=CC=C(Br)C=N1 OFKWIQJLYCKDNY-UHFFFAOYSA-N 0.000 description 5
- SKRNHHKIPSPIEF-XJKSGUPXSA-N N-[5-[[(2S,5R)-2-methyl-5-[(2-methylpyridin-4-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C[C@@H]1N(C[C@H](NC1)CC1=CC(=NC=C1)C)CC1=CN=C(S1)NC(C)=O SKRNHHKIPSPIEF-XJKSGUPXSA-N 0.000 description 5
- DLHWSDXEIZNPEU-GXFFZTMASA-N N-[5-[[(2S,5R)-5-[(5-fluoropyrimidin-2-yl)methyl]-2-methylpiperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C[C@H]1NC[C@@H](N(C1)CC1=CN=C(S1)NC(C)=O)C DLHWSDXEIZNPEU-GXFFZTMASA-N 0.000 description 5
- 101710081801 Protein O-GlcNAcase Proteins 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- KZLHASJXPLGUOE-UHFFFAOYSA-N n-(5-formyl-1,3-thiazol-2-yl)acetamide Chemical compound CC(=O)NC1=NC=C(C=O)S1 KZLHASJXPLGUOE-UHFFFAOYSA-N 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 5
- TXNLQUKVUJITMX-UHFFFAOYSA-N 4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine Chemical compound CC(C)(C)C1=CC=NC(C=2N=CC=C(C=2)C(C)(C)C)=C1 TXNLQUKVUJITMX-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- UPEHNEBSNNINGV-OAHLLOKOSA-N N-[5-[[(2R)-2-[(2-methylpyridin-4-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC=CC(=C1)C[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O UPEHNEBSNNINGV-OAHLLOKOSA-N 0.000 description 4
- YIQUVUBCEIBHOI-XJKSGUPXSA-N N-[5-[[(2S,5R)-2-methyl-5-[(6-methylpyridin-3-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C[C@@H]1N(C[C@H](NC1)CC=1C=NC(=CC=1)C)CC1=CN=C(S1)NC(C)=O YIQUVUBCEIBHOI-XJKSGUPXSA-N 0.000 description 4
- DBDDTOVEVBZYFY-HNNXBMFYSA-N N-[5-[[(3S)-3-[(2-methylpyridin-4-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC=CC(=C1)C[C@H]1CN(CCN1)CC1=CN=C(S1)NC(C)=O DBDDTOVEVBZYFY-HNNXBMFYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 230000007823 neuropathy Effects 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- PJXWCRXOPLGFLX-VIFPVBQESA-N (2s)-2-(benzylamino)propan-1-ol Chemical compound OC[C@H](C)NCC1=CC=CC=C1 PJXWCRXOPLGFLX-VIFPVBQESA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- JFBMFWHEXBLFCR-UHFFFAOYSA-N 4-bromo-2-methylpyridine Chemical compound CC1=CC(Br)=CC=N1 JFBMFWHEXBLFCR-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- SKUXMGBQJXBGDF-MRXNPFEDSA-N N-[5-[[(2R)-2-[(2-propan-2-yloxypyridin-4-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C(C)(C)OC1=NC=CC(=C1)C[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O SKUXMGBQJXBGDF-MRXNPFEDSA-N 0.000 description 3
- RPVJZOVKFKDERP-CQSZACIVSA-N N-[5-[[(2R)-2-[(5-fluoro-4-methylpyridin-2-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C(=CC(=NC=1)C[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O)C RPVJZOVKFKDERP-CQSZACIVSA-N 0.000 description 3
- WMTSEXGNMHLZTG-OAHLLOKOSA-N N-[5-[[(2R)-2-[(6-methylpyridin-3-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=CC=C(C=N1)C[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O WMTSEXGNMHLZTG-OAHLLOKOSA-N 0.000 description 3
- GWOQKAZOXVDCFP-CYBMUJFWSA-N N-[5-[[(2R)-2-[[2-(difluoromethyl)pyridin-4-yl]methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC(C1=NC=CC(=C1)C[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O)F GWOQKAZOXVDCFP-CYBMUJFWSA-N 0.000 description 3
- ATADEZVDAJLMLU-XJKSGUPXSA-N N-[5-[[(2R,5S)-5-methyl-2-[(2-methylpyridin-4-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C[C@@H]1N(C[C@H](OC1)CC1=CC(=NC=C1)C)CC1=CN=C(S1)NC(C)=O ATADEZVDAJLMLU-XJKSGUPXSA-N 0.000 description 3
- NGPZUGCQHYKRPF-WMLDXEAASA-N N-[5-[[(2S,5R)-2,4-dimethyl-5-[(6-methylpyridin-3-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C[C@@H]1N(C[C@H](N(C1)C)CC=1C=NC(=CC=1)C)CC1=CN=C(S1)NC(C)=O NGPZUGCQHYKRPF-WMLDXEAASA-N 0.000 description 3
- NKPLMGVYPZJZPK-SWLSCSKDSA-N N-[5-[[(2S,5R)-5-[(2-methoxypyridin-4-yl)methyl]-2-methylpiperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound COC1=NC=CC(=C1)C[C@H]1NC[C@@H](N(C1)CC1=CN=C(S1)NC(C)=O)C NKPLMGVYPZJZPK-SWLSCSKDSA-N 0.000 description 3
- ZKJAQPIYSJZZJY-YOEHRIQHSA-N N-[5-[[(2S,5S)-2-[(2,6-dimethylpyridin-4-yl)oxymethyl]-5-methylmorpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C(=O)(NC=1SC(=CN=1)CN1[C@@H](C)CO[C@@H](C1)COC1=CC(=NC(=C1)C)C)C ZKJAQPIYSJZZJY-YOEHRIQHSA-N 0.000 description 3
- CBXPADGVWMYEMV-MFKMUULPSA-N N-[5-[[(2S,6R)-2-[(5-fluoropyrimidin-2-yl)methyl]-6-methylmorpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C[C@@H]1O[C@@H](CN(C1)CC1=CN=C(S1)NC(C)=O)C CBXPADGVWMYEMV-MFKMUULPSA-N 0.000 description 3
- DBDDTOVEVBZYFY-OAHLLOKOSA-N N-[5-[[(3R)-3-[(2-methylpyridin-4-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC=CC(=C1)C[C@@H]1CN(CCN1)CC1=CN=C(S1)NC(C)=O DBDDTOVEVBZYFY-OAHLLOKOSA-N 0.000 description 3
- IOUZZBWPHFMTDB-UHFFFAOYSA-N N-[5-[[2-[(2,6-dimethylpyridin-4-yl)methyl]-1,4-oxazepan-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC(=CC(=C1)CC1OCCCN(C1)CC1=CN=C(S1)NC(C)=O)C IOUZZBWPHFMTDB-UHFFFAOYSA-N 0.000 description 3
- BEGHVKSAVGMVMK-UHFFFAOYSA-N N-[5-[[6-(hydroxymethyl)-4-methyl-1,4-diazepan-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound OCC1CN(CCN(C1)CC1=CN=C(S1)NC(C)=O)C BEGHVKSAVGMVMK-UHFFFAOYSA-N 0.000 description 3
- PAZLNWLYKGESLA-UHFFFAOYSA-N N-[5-[[6-[(2,6-dimethylpyridin-4-yl)methyl]-1,4-oxazepan-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC(=CC(=C1)CC1CN(CCOC1)CC1=CN=C(S1)NC(C)=O)C PAZLNWLYKGESLA-UHFFFAOYSA-N 0.000 description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 3
- UBXCHNAJKMBEJB-HKUYNNGSSA-N benzyl (2S,5S)-2-[(2,6-dimethylpyridin-4-yl)oxymethyl]-5-methylpiperazine-1-carboxylate Chemical compound CC1=NC(=CC(=C1)OC[C@H]1N(C[C@@H](NC1)C)C(=O)OCC1=CC=CC=C1)C UBXCHNAJKMBEJB-HKUYNNGSSA-N 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 3
- 239000005416 organic matter Substances 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- UFYBTLOLWSABAU-UHFFFAOYSA-N (2-methylpyridin-4-yl)boronic acid Chemical compound CC1=CC(B(O)O)=CC=N1 UFYBTLOLWSABAU-UHFFFAOYSA-N 0.000 description 2
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 2
- CBEYLKFPNGYBSS-UHFFFAOYSA-N 1-O-benzyl 4-O-tert-butyl 2-(bromomethyl)-1,4-diazepane-1,4-dicarboxylate Chemical compound BrCC1N(CCCN(C1)C(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1 CBEYLKFPNGYBSS-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 2
- SQTLUXJWUCHKMT-UHFFFAOYSA-N 4-bromo-n,n-diphenylaniline Chemical compound C1=CC(Br)=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 SQTLUXJWUCHKMT-UHFFFAOYSA-N 0.000 description 2
- OKWDDQLIGHSFEA-UHFFFAOYSA-N 4-o-benzyl 1-o-tert-butyl 2-(hydroxymethyl)piperazine-1,4-dicarboxylate Chemical compound C1C(CO)N(C(=O)OC(C)(C)C)CCN1C(=O)OCC1=CC=CC=C1 OKWDDQLIGHSFEA-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- AHRSMLYBTXZIQE-UHFFFAOYSA-N CC(Nc1ncc(CN2CC(C[AlH2])COCC2)[s]1)=O Chemical compound CC(Nc1ncc(CN2CC(C[AlH2])COCC2)[s]1)=O AHRSMLYBTXZIQE-UHFFFAOYSA-N 0.000 description 2
- WMTJWKKKJCOHFA-UHFFFAOYSA-N CC(Nc1ncc(CN2CC(C[AlH2])OCCC2)[s]1)=O Chemical compound CC(Nc1ncc(CN2CC(C[AlH2])OCCC2)[s]1)=O WMTJWKKKJCOHFA-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MDUZWICIRWGKLU-UHFFFAOYSA-N N-(4-fluoro-5-formyl-1,3-thiazol-2-yl)acetamide Chemical compound FC=1N=C(SC=1C=O)NC(C)=O MDUZWICIRWGKLU-UHFFFAOYSA-N 0.000 description 2
- UAWVNARKCWKZQK-CQSZACIVSA-N N-[4-fluoro-5-[[(2R)-2-[(6-methylpyridin-3-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1N=C(SC=1CN1C[C@H](OCC1)CC=1C=NC(=CC=1)C)NC(C)=O UAWVNARKCWKZQK-CQSZACIVSA-N 0.000 description 2
- BOAYBFCXZJXWJQ-SWLSCSKDSA-N N-[4-fluoro-5-[[(2R,5S)-5-methyl-2-[(6-methylpyridin-3-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C[C@H]1CO[C@@H](CN1CC2=C(N=C(S2)NC(=O)C)F)CC3=CN=C(C=C3)C BOAYBFCXZJXWJQ-SWLSCSKDSA-N 0.000 description 2
- CKCNTRWEWCYWRW-ZWNOBZJWSA-N N-[5-[(1R)-1-[(2R)-2-[(5-fluoropyrimidin-2-yl)methyl]morpholin-4-yl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C[C@H]1OCCN(C1)[C@H](C)C1=CN=C(S1)NC(C)=O CKCNTRWEWCYWRW-ZWNOBZJWSA-N 0.000 description 2
- UAKOYONQJVHHDM-MRXNPFEDSA-N N-[5-[[(2R)-2-[(2,6-dimethylpyridin-4-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC(=CC(=C1)C[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O)C UAKOYONQJVHHDM-MRXNPFEDSA-N 0.000 description 2
- VHEGOZLHORHOJQ-OAHLLOKOSA-N N-[5-[[(2R)-2-[(2-ethoxypyridin-4-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C(C)OC1=NC=CC(=C1)C[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O VHEGOZLHORHOJQ-OAHLLOKOSA-N 0.000 description 2
- IXLZVUWKAGCHSA-OAHLLOKOSA-N N-[5-[[(2R)-2-[(2-methoxy-3-methylpyridin-4-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound COC1=NC=CC(=C1C)C[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O IXLZVUWKAGCHSA-OAHLLOKOSA-N 0.000 description 2
- UOACLMGUJINVGI-CQSZACIVSA-N N-[5-[[(2R)-2-[(2-methoxypyridin-4-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound COC1=NC=CC(=C1)C[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O UOACLMGUJINVGI-CQSZACIVSA-N 0.000 description 2
- UPXMCMUGGASOAJ-CYBMUJFWSA-N N-[5-[[(2R)-2-[(2-methoxypyrimidin-4-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound COC1=NC=CC(=N1)C[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O UPXMCMUGGASOAJ-CYBMUJFWSA-N 0.000 description 2
- WPTALUWAMVUMMP-CQSZACIVSA-N N-[5-[[(2R)-2-[(2-methylpyrimidin-4-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC=CC(=N1)C[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O WPTALUWAMVUMMP-CQSZACIVSA-N 0.000 description 2
- RLJSRKUMWMFWIG-CYBMUJFWSA-N N-[5-[[(2R)-2-[(3-fluoro-2-methoxypyridin-4-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C(=NC=CC=1C[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O)OC RLJSRKUMWMFWIG-CYBMUJFWSA-N 0.000 description 2
- MUYJQPMZAPFCBB-CQSZACIVSA-N N-[5-[[(2R)-2-[(4-fluoro-3-methoxyphenyl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC1=C(C=C(C[C@H]2OCCN(C2)CC2=CN=C(S2)NC(C)=O)C=C1)OC MUYJQPMZAPFCBB-CQSZACIVSA-N 0.000 description 2
- APTCRJUDTCCUPA-CYBMUJFWSA-N N-[5-[[(2R)-2-[(5-fluoropyrimidin-2-yl)methyl]-1,4-oxazepan-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C[C@H]1OCCCN(C1)CC1=CN=C(S1)NC(C)=O APTCRJUDTCCUPA-CYBMUJFWSA-N 0.000 description 2
- DHOCHFDQUZRPKM-GFCCVEGCSA-N N-[5-[[(2R)-2-[(5-fluoropyrimidin-2-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O DHOCHFDQUZRPKM-GFCCVEGCSA-N 0.000 description 2
- YUIOTNGNLOIEGK-OAHLLOKOSA-N N-[5-[[(2R)-2-[(5-methylpyridin-2-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC=1C=CC(=NC=1)C[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O YUIOTNGNLOIEGK-OAHLLOKOSA-N 0.000 description 2
- KIBMXHMAALEXRG-CYBMUJFWSA-N N-[5-[[(2R)-2-[(6-methoxypyrimidin-4-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound COC1=CC(=NC=N1)C[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O KIBMXHMAALEXRG-CYBMUJFWSA-N 0.000 description 2
- OEHLULWLSGUZBV-CQSZACIVSA-N N-[5-[[(2R)-2-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC(COC1=NC=CC(=C1)C[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O)(F)F OEHLULWLSGUZBV-CQSZACIVSA-N 0.000 description 2
- DNZPIMBYRAXPHD-CYBMUJFWSA-N N-[5-[[(2R)-2-[[2-(difluoromethoxy)pyridin-4-yl]methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC(OC1=NC=CC(=C1)C[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O)F DNZPIMBYRAXPHD-CYBMUJFWSA-N 0.000 description 2
- AKRYOOPOKFIGFA-GFCCVEGCSA-N N-[5-[[(2R)-2-[[2-(trifluoromethyl)pyrimidin-4-yl]methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC(C1=NC=CC(=N1)C[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O)(F)F AKRYOOPOKFIGFA-GFCCVEGCSA-N 0.000 description 2
- YXEZBFKNGLZGDQ-WMLDXEAASA-N N-[5-[[(2R,5S)-2-[(2,6-dimethylpyridin-4-yl)methyl]-5-methylmorpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC(=CC(=C1)C[C@H]1OC[C@@H](N(C1)CC1=CN=C(S1)NC(C)=O)C)C YXEZBFKNGLZGDQ-WMLDXEAASA-N 0.000 description 2
- LMPRQFAAVNSRFO-GXFFZTMASA-N N-[5-[[(2R,5S)-2-[(5-fluoropyrimidin-2-yl)methyl]-5-methylmorpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C[C@H]1OC[C@@H](N(C1)CC1=CN=C(S1)NC(C)=O)C LMPRQFAAVNSRFO-GXFFZTMASA-N 0.000 description 2
- FLKYZDFENKETEM-XJKSGUPXSA-N N-[5-[[(2R,5S)-5-methyl-2-[(6-methylpyridin-3-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C[C@@H]1N(C[C@H](OC1)CC=1C=NC(=CC=1)C)CC1=CN=C(S1)NC(C)=O FLKYZDFENKETEM-XJKSGUPXSA-N 0.000 description 2
- AHWJLTMIBBXTPW-IINYFYTJSA-N N-[5-[[(2S)-2-[(1R)-1-(5-fluoropyrimidin-2-yl)ethyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)[C@@H](C)[C@@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O AHWJLTMIBBXTPW-IINYFYTJSA-N 0.000 description 2
- AHWJLTMIBBXTPW-QMTHXVAHSA-N N-[5-[[(2S)-2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)[C@H](C)[C@@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O AHWJLTMIBBXTPW-QMTHXVAHSA-N 0.000 description 2
- UOACLMGUJINVGI-AWEZNQCLSA-N N-[5-[[(2S)-2-[(2-methoxypyridin-4-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound COC1=NC=CC(=C1)C[C@@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O UOACLMGUJINVGI-AWEZNQCLSA-N 0.000 description 2
- APTCRJUDTCCUPA-ZDUSSCGKSA-N N-[5-[[(2S)-2-[(5-fluoropyrimidin-2-yl)methyl]-1,4-oxazepan-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C[C@@H]1OCCCN(C1)CC1=CN=C(S1)NC(C)=O APTCRJUDTCCUPA-ZDUSSCGKSA-N 0.000 description 2
- RVPIOQGRJMKYOU-WMLDXEAASA-N N-[5-[[(2S,5R)-2,4-dimethyl-5-[(2-methylpyridin-4-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C[C@@H]1N(C[C@H](N(C1)C)CC1=CC(=NC=C1)C)CC1=CN=C(S1)NC(C)=O RVPIOQGRJMKYOU-WMLDXEAASA-N 0.000 description 2
- LMPRQFAAVNSRFO-MFKMUULPSA-N N-[5-[[(2S,5R)-2-[(5-fluoropyrimidin-2-yl)methyl]-5-methylmorpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C[C@@H]1OC[C@H](N(C1)CC1=CN=C(S1)NC(C)=O)C LMPRQFAAVNSRFO-MFKMUULPSA-N 0.000 description 2
- GBSYMQCLDUQBRA-MAUKXSAKSA-N N-[5-[[(2S,5R)-4-ethyl-2-methyl-5-[(2-methylpyridin-4-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C(C)N1C[C@@H](N(C[C@H]1CC1=CC(=NC=C1)C)CC1=CN=C(S1)NC(C)=O)C GBSYMQCLDUQBRA-MAUKXSAKSA-N 0.000 description 2
- SSQLMVXKAZGLCO-MAUKXSAKSA-N N-[5-[[(2S,5R)-4-ethyl-2-methyl-5-[(6-methylpyridin-3-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C(C)N1C[C@@H](N(C[C@H]1CC=1C=NC(=CC=1)C)CC1=CN=C(S1)NC(C)=O)C SSQLMVXKAZGLCO-MAUKXSAKSA-N 0.000 description 2
- AJOZQCHSOPIQRS-MAUKXSAKSA-N N-[5-[[(2S,5R)-5-[(2,6-dimethylpyridin-4-yl)methyl]-2,4-dimethylpiperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC(=CC(=C1)C[C@H]1N(C[C@@H](N(C1)CC1=CN=C(S1)NC(C)=O)C)C)C AJOZQCHSOPIQRS-MAUKXSAKSA-N 0.000 description 2
- DAAFSYAVJKYQKH-WMLDXEAASA-N N-[5-[[(2S,5R)-5-[(2,6-dimethylpyridin-4-yl)methyl]-2-methylpiperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC(=CC(=C1)C[C@H]1NC[C@@H](N(C1)CC1=CN=C(S1)NC(C)=O)C)C DAAFSYAVJKYQKH-WMLDXEAASA-N 0.000 description 2
- WDOOIENVVZAYNR-SUMWQHHRSA-N N-[5-[[(2S,5R)-5-[(2,6-dimethylpyrimidin-4-yl)methyl]-2,4-dimethylpiperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC(=CC(=N1)C[C@H]1N(C[C@@H](N(C1)CC1=CN=C(S1)NC(C)=O)C)C)C WDOOIENVVZAYNR-SUMWQHHRSA-N 0.000 description 2
- QZHLILJQEZNUFD-BLLLJJGKSA-N N-[5-[[(2S,5R)-5-[(2,6-dimethylpyrimidin-4-yl)methyl]-2-methylpiperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC(=CC(=N1)C[C@H]1NC[C@@H](N(C1)CC1=CN=C(S1)NC(C)=O)C)C QZHLILJQEZNUFD-BLLLJJGKSA-N 0.000 description 2
- GSGNCNFCVQMVPG-XJKSGUPXSA-N N-[5-[[(2S,5R)-5-[(2-methoxypyridin-4-yl)methyl]-2,4-dimethylpiperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound COC1=NC=CC(=C1)C[C@H]1N(C[C@@H](N(C1)CC1=CN=C(S1)NC(C)=O)C)C GSGNCNFCVQMVPG-XJKSGUPXSA-N 0.000 description 2
- XTAPFVXZKLENPI-SMDDNHRTSA-N N-[5-[[(2S,5R)-5-[(5-fluoropyrimidin-2-yl)methyl]-2,4-dimethylpiperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C[C@H]1N(C[C@@H](N(C1)CC1=CN=C(S1)NC(C)=O)C)C XTAPFVXZKLENPI-SMDDNHRTSA-N 0.000 description 2
- LMPRQFAAVNSRFO-GWCFXTLKSA-N N-[5-[[(2S,5S)-2-[(5-fluoropyrimidin-2-yl)methyl]-5-methylmorpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C[C@@H]1OC[C@@H](N(C1)CC1=CN=C(S1)NC(C)=O)C LMPRQFAAVNSRFO-GWCFXTLKSA-N 0.000 description 2
- NNKUCWYRFQZUCQ-OAHLLOKOSA-N N-[5-[[(3R)-3-[(6-methylpyridin-3-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=CC=C(C=N1)C[C@@H]1CN(CCN1)CC1=CN=C(S1)NC(C)=O NNKUCWYRFQZUCQ-OAHLLOKOSA-N 0.000 description 2
- PQDXGGJQZXJUGX-KRWDZBQOSA-N N-[5-[[(3S)-3-[(2,6-dimethylpyridin-4-yl)methyl]-4-methylpiperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC(=CC(=C1)C[C@H]1CN(CCN1C)CC1=CN=C(S1)NC(C)=O)C PQDXGGJQZXJUGX-KRWDZBQOSA-N 0.000 description 2
- SZZAVXYBHLJLED-NTISSMGPSA-N N-[5-[[(3S)-3-[(2,6-dimethylpyridin-4-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide hydrochloride Chemical compound Cl.C(C)(=O)NC=1SC(=CN1)CN1C[C@@H](NCC1)CC1=CC(=NC(=C1)C)C SZZAVXYBHLJLED-NTISSMGPSA-N 0.000 description 2
- NNKUCWYRFQZUCQ-HNNXBMFYSA-N N-[5-[[(3S)-3-[(6-methylpyridin-3-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=CC=C(C=N1)C[C@H]1CN(CCN1)CC1=CN=C(S1)NC(C)=O NNKUCWYRFQZUCQ-HNNXBMFYSA-N 0.000 description 2
- ANMJKGILRRDWIX-INIZCTEOSA-N N-[5-[[(3S)-4-methyl-3-[(2-methylpyridin-4-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CN1[C@H](CN(CC1)CC1=CN=C(S1)NC(C)=O)CC1=CC(=NC=C1)C ANMJKGILRRDWIX-INIZCTEOSA-N 0.000 description 2
- XVFLCRIZIQNQBZ-UHFFFAOYSA-N N-[5-[[2-[(2-methoxypyridin-4-yl)methyl]-1,4-oxazepan-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound COC1=NC=CC(=C1)CC1OCCCN(C1)CC1=CN=C(S1)NC(C)=O XVFLCRIZIQNQBZ-UHFFFAOYSA-N 0.000 description 2
- APTCRJUDTCCUPA-UHFFFAOYSA-N N-[5-[[2-[(5-fluoropyrimidin-2-yl)methyl]-1,4-oxazepan-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)CC1OCCCN(C1)CC1=CN=C(S1)NC(C)=O APTCRJUDTCCUPA-UHFFFAOYSA-N 0.000 description 2
- ZVVMQDFCSHGSQZ-UHFFFAOYSA-N N-[5-[[3-[(2,6-dimethylpyridin-4-yl)methyl]-1,4-diazepan-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC(=CC(=C1)CC1CN(CCCN1)CC1=CN=C(S1)NC(C)=O)C ZVVMQDFCSHGSQZ-UHFFFAOYSA-N 0.000 description 2
- MIGMUBJKKNTZIN-UHFFFAOYSA-N N-[5-[[3-[(2-methoxypyridin-4-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound COC1=NC=CC(=C1)CC1CN(CCN1)CC1=CN=C(S1)NC(C)=O MIGMUBJKKNTZIN-UHFFFAOYSA-N 0.000 description 2
- KIUWVFORSLTVSL-UHFFFAOYSA-N N-[5-[[3-[(4-fluoro-3-methoxyphenyl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC1=C(C=C(CC2CN(CCN2)CC2=CN=C(S2)NC(C)=O)C=C1)OC KIUWVFORSLTVSL-UHFFFAOYSA-N 0.000 description 2
- ZKFDBHAIURQXMJ-UHFFFAOYSA-N N-[5-[[3-[(5-fluoropyrimidin-2-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)CC1CN(CCN1)CC1=CN=C(S1)NC(C)=O ZKFDBHAIURQXMJ-UHFFFAOYSA-N 0.000 description 2
- YVLPFTBBHQCTOI-UHFFFAOYSA-N N-[5-[[4-acetyl-3-[(2,6-dimethylpyridin-4-yl)methyl]-1,4-diazepan-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C(C)(=O)N1C(CN(CCC1)CC1=CN=C(S1)NC(C)=O)CC1=CC(=NC(=C1)C)C YVLPFTBBHQCTOI-UHFFFAOYSA-N 0.000 description 2
- MENIMQQQHRJRHW-UHFFFAOYSA-N N-[5-[[6-[(2-methoxypyridin-4-yl)methyl]-1,4-oxazepan-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound COC1=NC=CC(=C1)CC1CN(CCOC1)CC1=CN=C(S1)NC(C)=O MENIMQQQHRJRHW-UHFFFAOYSA-N 0.000 description 2
- ATWRQLOWQHBYHG-UHFFFAOYSA-N N-[5-[[6-[(5-fluoropyrimidin-2-yl)methyl]-1,4-oxazepan-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)CC1CN(CCOC1)CC1=CN=C(S1)NC(C)=O ATWRQLOWQHBYHG-UHFFFAOYSA-N 0.000 description 2
- RORBPUQXFOZVQX-UHFFFAOYSA-N N-[5-[[6-[(5-fluoropyrimidin-2-yl)oxymethyl]-4-methyl-1,4-diazepan-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)OCC1CN(CCN(C1)CC1=CN=C(S1)NC(C)=O)C RORBPUQXFOZVQX-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108010077991 O-GlcNAc transferase Proteins 0.000 description 2
- 102000005520 O-GlcNAc transferase Human genes 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- KEXVIAQYBSMHRA-REWPJTCUSA-N benzyl (2S,5S)-4-[(2-acetamido-1,3-thiazol-5-yl)methyl]-2-[(2,6-dimethylpyridin-4-yl)oxymethyl]-5-methylpiperazine-1-carboxylate Chemical compound C(C)(=O)NC=1SC(=CN=1)CN1C[C@H](N(C[C@@H]1C)C(=O)OCC1=CC=CC=C1)COC1=CC(=NC(=C1)C)C KEXVIAQYBSMHRA-REWPJTCUSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- OBJOQVLWWLTNLQ-BDAKNGLRSA-N tert-butyl (2R,5R)-2-(bromomethyl)-5-methylmorpholine-4-carboxylate Chemical compound BrC[C@H]1CN([C@@H](CO1)C)C(=O)OC(C)(C)C OBJOQVLWWLTNLQ-BDAKNGLRSA-N 0.000 description 2
- QGEFRGPCFOEDNF-IUCAKERBSA-N tert-butyl (2S,5S)-2-(hydroxymethyl)-5-methylmorpholine-4-carboxylate Chemical compound OC[C@@H]1CN([C@H](CO1)C)C(=O)OC(C)(C)C QGEFRGPCFOEDNF-IUCAKERBSA-N 0.000 description 2
- CWXGHLFJGHFNLF-DTWKUNHWSA-N tert-butyl (2S,6S)-2-(bromomethyl)-6-methylmorpholine-4-carboxylate Chemical compound BrC[C@@H]1CN(C[C@@H](O1)C)C(=O)OC(C)(C)C CWXGHLFJGHFNLF-DTWKUNHWSA-N 0.000 description 2
- YJPPRECNUURDRC-IUCAKERBSA-N tert-butyl (2S,6S)-2-(hydroxymethyl)-6-methylmorpholine-4-carboxylate Chemical compound C[C@H]1CN(C[C@@H](CO)O1)C(=O)OC(C)(C)C YJPPRECNUURDRC-IUCAKERBSA-N 0.000 description 2
- YISREGIVFNMYSB-UHFFFAOYSA-N tert-butyl 2-(1-hydroxyethyl)morpholine-4-carboxylate Chemical compound CC(O)C1CN(C(=O)OC(C)(C)C)CCO1 YISREGIVFNMYSB-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- CUIRRVACBQLGDI-UHFFFAOYSA-N (1-methyl-1,4-diazepan-6-yl)methanol Chemical compound CN1CCNCC(CO)C1 CUIRRVACBQLGDI-UHFFFAOYSA-N 0.000 description 1
- DHQMUJSACXTPEA-UHFFFAOYSA-N (2-methoxypyridin-4-yl)boronic acid Chemical compound COC1=CC(B(O)O)=CC=N1 DHQMUJSACXTPEA-UHFFFAOYSA-N 0.000 description 1
- GRGHWUROSPBKML-DDWIOCJRSA-N (2R)-2-[(5-fluoropyrimidin-2-yl)methyl]morpholine hydrochloride Chemical compound Cl.FC=1C=NC(=NC=1)C[C@H]1OCCNC1 GRGHWUROSPBKML-DDWIOCJRSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- PJXWCRXOPLGFLX-SECBINFHSA-N (2r)-2-(benzylamino)propan-1-ol Chemical compound OC[C@@H](C)NCC1=CC=CC=C1 PJXWCRXOPLGFLX-SECBINFHSA-N 0.000 description 1
- IJMIYSXHHOKJEZ-HTQZYQBOSA-N (2r,6r)-6-methyl-4-[(2-methylpropan-2-yl)oxycarbonyl]morpholine-2-carboxylic acid Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)C[C@H](C(O)=O)O1 IJMIYSXHHOKJEZ-HTQZYQBOSA-N 0.000 description 1
- LUJMSRVFSBMEOY-UHFFFAOYSA-N (4-fluoro-3-methoxyphenyl)boronic acid Chemical compound COC1=CC(B(O)O)=CC=C1F LUJMSRVFSBMEOY-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- DKYUQDAGSUBDRU-GOEBONIOSA-N 1-O-benzyl 4-O-tert-butyl (2S,5S)-2-(bromomethyl)-5-methylpiperazine-1,4-dicarboxylate Chemical compound BrC[C@H]1N(C[C@@H](N(C1)C(=O)OC(C)(C)C)C)C(=O)OCC1=CC=CC=C1 DKYUQDAGSUBDRU-GOEBONIOSA-N 0.000 description 1
- DVPLXTZRAMPJQO-HOCLYGCPSA-N 1-O-benzyl 4-O-tert-butyl (2S,5S)-2-(hydroxymethyl)-5-methylpiperazine-1,4-dicarboxylate Chemical compound OC[C@H]1N(C[C@@H](N(C1)C(=O)OC(C)(C)C)C)C(=O)OCC1=CC=CC=C1 DVPLXTZRAMPJQO-HOCLYGCPSA-N 0.000 description 1
- WORHEYXDSZCBSF-UHFFFAOYSA-N 1-O-benzyl 4-O-tert-butyl 2-(methylsulfonyloxymethyl)-1,4-diazepane-1,4-dicarboxylate Chemical compound CS(=O)(=O)OCC1N(CCCN(C1)C(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1 WORHEYXDSZCBSF-UHFFFAOYSA-N 0.000 description 1
- ZZTOQHFGOXDWBO-UHFFFAOYSA-N 1-O-benzyl 4-O-tert-butyl 2-[(5-fluoropyrimidin-2-yl)methyl]-1,4-diazepane-1,4-dicarboxylate Chemical compound FC=1C=NC(=NC=1)CC1N(CCCN(C1)C(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1 ZZTOQHFGOXDWBO-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- 125000006083 1-bromoethyl group Chemical group 0.000 description 1
- DZCBKUAAGVVLOX-UHFFFAOYSA-N 1-morpholin-4-ylethanol Chemical compound CC(O)N1CCOCC1 DZCBKUAAGVVLOX-UHFFFAOYSA-N 0.000 description 1
- RGRDUBAOCARAEX-UHFFFAOYSA-N 1-o-benzyl 4-o-tert-butyl 2-(hydroxymethyl)-1,4-diazepane-1,4-dicarboxylate Chemical compound OCC1CN(C(=O)OC(C)(C)C)CCCN1C(=O)OCC1=CC=CC=C1 RGRDUBAOCARAEX-UHFFFAOYSA-N 0.000 description 1
- UINOMZOGOKYFHD-UHFFFAOYSA-N 1-o-benzyl 4-o-tert-butyl 2-(hydroxymethyl)piperazine-1,4-dicarboxylate Chemical compound OCC1CN(C(=O)OC(C)(C)C)CCN1C(=O)OCC1=CC=CC=C1 UINOMZOGOKYFHD-UHFFFAOYSA-N 0.000 description 1
- BRXKHIPPSTYCKO-UHFFFAOYSA-N 1-o-tert-butyl 2-o-methyl piperazine-1,2-dicarboxylate Chemical compound COC(=O)C1CNCCN1C(=O)OC(C)(C)C BRXKHIPPSTYCKO-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- PRAFLUMTYHBEHE-UHFFFAOYSA-N 2,6-dimethyl-1h-pyridin-4-one Chemical compound CC1=CC(O)=CC(C)=N1 PRAFLUMTYHBEHE-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- VISSEGPUIOBULE-UHFFFAOYSA-N 2-[[1-[(2-methylpropan-2-yl)oxycarbonyl]-4-phenylmethoxycarbonylpiperazin-2-yl]methoxy]-2-oxoacetic acid Chemical compound C(C1=CC=CC=C1)OC(=O)N1CC(N(CC1)C(=O)OC(C)(C)C)COC(C(=O)O)=O VISSEGPUIOBULE-UHFFFAOYSA-N 0.000 description 1
- YWNJQQNBJQUKME-UHFFFAOYSA-N 2-bromo-5-methylpyridine Chemical compound CC1=CC=C(Br)N=C1 YWNJQQNBJQUKME-UHFFFAOYSA-N 0.000 description 1
- HWDRAVIZSYVICK-UHFFFAOYSA-N 2-chloro-5-fluoro-4-methylpyridine Chemical compound CC1=CC(Cl)=NC=C1F HWDRAVIZSYVICK-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- RNXJYUYQEAPJSK-RDJZCZTQSA-N 4-O-benzyl 1-O-tert-butyl (2S,5S)-2-methyl-5-(methylsulfonyloxymethyl)piperazine-1,4-dicarboxylate Chemical compound C[C@@H]1N(C[C@H](N(C1)C(=O)OCC1=CC=CC=C1)COS(=O)(=O)C)C(=O)OC(C)(C)C RNXJYUYQEAPJSK-RDJZCZTQSA-N 0.000 description 1
- SEVMQEIGENUPIE-UHFFFAOYSA-N 4-bromo-1-fluoro-2-methoxybenzene Chemical compound COC1=CC(Br)=CC=C1F SEVMQEIGENUPIE-UHFFFAOYSA-N 0.000 description 1
- PTCKNLGMBFKIFP-UHFFFAOYSA-N 4-bromo-2,6-dimethylpyrimidine Chemical compound CC1=CC(Br)=NC(C)=N1 PTCKNLGMBFKIFP-UHFFFAOYSA-N 0.000 description 1
- QZFCOYMEICRTCT-UHFFFAOYSA-N 4-bromo-2-(2,2,2-trifluoroethoxy)pyridine Chemical compound FC(F)(F)COC1=CC(Br)=CC=N1 QZFCOYMEICRTCT-UHFFFAOYSA-N 0.000 description 1
- QKZHLBZNEBCOLM-UHFFFAOYSA-N 4-bromo-2-(difluoromethoxy)pyridine Chemical compound FC(F)OC1=CC(Br)=CC=N1 QKZHLBZNEBCOLM-UHFFFAOYSA-N 0.000 description 1
- MNMLGZMORMDPJI-UHFFFAOYSA-N 4-bromo-2-(difluoromethyl)pyridine Chemical compound FC(F)C1=CC(Br)=CC=N1 MNMLGZMORMDPJI-UHFFFAOYSA-N 0.000 description 1
- XHPRAYURZWKYAV-UHFFFAOYSA-N 4-bromo-2-ethoxypyridine Chemical compound CCOC1=CC(Br)=CC=N1 XHPRAYURZWKYAV-UHFFFAOYSA-N 0.000 description 1
- MXNUOXFGYYUHJI-UHFFFAOYSA-N 4-bromo-2-methoxy-3-methylpyridine Chemical compound COC1=NC=CC(Br)=C1C MXNUOXFGYYUHJI-UHFFFAOYSA-N 0.000 description 1
- DGDIOQCZNZMIPA-UHFFFAOYSA-N 4-bromo-2-propan-2-yloxypyridine Chemical compound CC(C)OC1=CC(Br)=CC=N1 DGDIOQCZNZMIPA-UHFFFAOYSA-N 0.000 description 1
- NYMSNXYJKHEMCQ-UHFFFAOYSA-N 4-bromo-3-fluoro-2-methoxypyridine Chemical compound COC1=NC=CC(Br)=C1F NYMSNXYJKHEMCQ-UHFFFAOYSA-N 0.000 description 1
- OVEGSCLVOXWLIV-UHFFFAOYSA-N 4-chloro-2-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=NC=CC(Cl)=N1 OVEGSCLVOXWLIV-UHFFFAOYSA-N 0.000 description 1
- XCAMEGPUILTZSU-UHFFFAOYSA-N 4-chloro-2-methoxypyrimidine Chemical compound COC1=NC=CC(Cl)=N1 XCAMEGPUILTZSU-UHFFFAOYSA-N 0.000 description 1
- WDTVJRYCMIZPMX-UHFFFAOYSA-N 4-chloro-2-methylpyrimidine Chemical compound CC1=NC=CC(Cl)=N1 WDTVJRYCMIZPMX-UHFFFAOYSA-N 0.000 description 1
- KLJGSQVYUGQOAW-UHFFFAOYSA-N 4-chloro-6-methoxypyrimidine Chemical compound COC1=CC(Cl)=NC=N1 KLJGSQVYUGQOAW-UHFFFAOYSA-N 0.000 description 1
- GXVOIJWTXUNBIQ-UHFFFAOYSA-N 4-o-benzyl 1-o-tert-butyl 2-formylpiperazine-1,4-dicarboxylate Chemical compound C1C(C=O)N(C(=O)OC(C)(C)C)CCN1C(=O)OCC1=CC=CC=C1 GXVOIJWTXUNBIQ-UHFFFAOYSA-N 0.000 description 1
- KSPDSMOWMQFPBL-UHFFFAOYSA-N 5-fluoropyrimidine Chemical compound FC1=CN=CN=C1 KSPDSMOWMQFPBL-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010055851 Acetylglucosaminidase Proteins 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- KILMERKTXJDXTK-UHFFFAOYSA-N Bc1ccnc(O)c1 Chemical compound Bc1ccnc(O)c1 KILMERKTXJDXTK-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OBJOQVLWWLTNLQ-DTWKUNHWSA-N BrC[C@@H]1CN([C@H](CO1)C)C(=O)OC(C)(C)C Chemical compound BrC[C@@H]1CN([C@H](CO1)C)C(=O)OC(C)(C)C OBJOQVLWWLTNLQ-DTWKUNHWSA-N 0.000 description 1
- OBJOQVLWWLTNLQ-IUCAKERBSA-N BrC[C@H]1CN([C@H](CO1)C)C(=O)OC(C)(C)C Chemical compound BrC[C@H]1CN([C@H](CO1)C)C(=O)OC(C)(C)C OBJOQVLWWLTNLQ-IUCAKERBSA-N 0.000 description 1
- AGQIINBWFLLVJY-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCCOC(CBr)C1 Chemical compound CC(C)(C)OC(=O)N1CCCOC(CBr)C1 AGQIINBWFLLVJY-UHFFFAOYSA-N 0.000 description 1
- UUIMDJFBHNDZOW-UHFFFAOYSA-N CC(C)(C)c1ccccn1 Chemical compound CC(C)(C)c1ccccn1 UUIMDJFBHNDZOW-UHFFFAOYSA-N 0.000 description 1
- PXEJBTJCBLQUKS-UHFFFAOYSA-N CC(C)(C)c1ncccn1 Chemical compound CC(C)(C)c1ncccn1 PXEJBTJCBLQUKS-UHFFFAOYSA-N 0.000 description 1
- TUQFKAVXEIIJPG-PXYINDEMSA-N CC(C)OCC(C1)O[C@@H](C)CN1C(OC(C)(C)C)=O Chemical compound CC(C)OCC(C1)O[C@@H](C)CN1C(OC(C)(C)C)=O TUQFKAVXEIIJPG-PXYINDEMSA-N 0.000 description 1
- DBDDTOVEVBZYFY-UHFFFAOYSA-N CC(Nc1ncc(CN2CC(Cc3cc(C)ncc3)NCC2)[s]1)=O Chemical compound CC(Nc1ncc(CN2CC(Cc3cc(C)ncc3)NCC2)[s]1)=O DBDDTOVEVBZYFY-UHFFFAOYSA-N 0.000 description 1
- RGDNULMAFMHWMF-OAHLLOKOSA-N CC(Nc1ncc(CN2C[C@@H](Cc3cc(OC)ncc3)N(C)CC2)[s]1)=O Chemical compound CC(Nc1ncc(CN2C[C@@H](Cc3cc(OC)ncc3)N(C)CC2)[s]1)=O RGDNULMAFMHWMF-OAHLLOKOSA-N 0.000 description 1
- OVRUMUHNAWMPEQ-LWKPJOBUSA-N CC(Nc1ncc(CN2C[C@H](Cc3cc(C)nc(C)c3)N(C)CC2)[s]1)O Chemical compound CC(Nc1ncc(CN2C[C@H](Cc3cc(C)nc(C)c3)N(C)CC2)[s]1)O OVRUMUHNAWMPEQ-LWKPJOBUSA-N 0.000 description 1
- RGDNULMAFMHWMF-HNNXBMFYSA-N CC(Nc1ncc(CN2C[C@H](Cc3ccnc(OC)c3)N(C)CC2)[s]1)=O Chemical compound CC(Nc1ncc(CN2C[C@H](Cc3ccnc(OC)c3)N(C)CC2)[s]1)=O RGDNULMAFMHWMF-HNNXBMFYSA-N 0.000 description 1
- NUYVFWGLMVZYPJ-UNMCSNQZSA-N CC1=NC(=CC(=C1)OC[C@H]1N(C[C@@H](N(C1)C(=O)OC(C)(C)C)C)C(=O)OCC1=CC=CC=C1)C Chemical compound CC1=NC(=CC(=C1)OC[C@H]1N(C[C@@H](N(C1)C(=O)OC(C)(C)C)C)C(=O)OCC1=CC=CC=C1)C NUYVFWGLMVZYPJ-UNMCSNQZSA-N 0.000 description 1
- RVPIOQGRJMKYOU-FBMWCMRBSA-N CC1N(Cc2cnc(NC(C)=O)[s]2)C[C@@H](Cc2ccnc(C)c2)N(C)C1 Chemical compound CC1N(Cc2cnc(NC(C)=O)[s]2)C[C@@H](Cc2ccnc(C)c2)N(C)C1 RVPIOQGRJMKYOU-FBMWCMRBSA-N 0.000 description 1
- MFEIKQPHQINPRI-UHFFFAOYSA-N CCc1cccnc1 Chemical compound CCc1cccnc1 MFEIKQPHQINPRI-UHFFFAOYSA-N 0.000 description 1
- CWXGHLFJGHFNLF-IENPIDJESA-N C[C@@H](C1)OC(CBr)CN1C(OC(C)(C)C)=O Chemical compound C[C@@H](C1)OC(CBr)CN1C(OC(C)(C)C)=O CWXGHLFJGHFNLF-IENPIDJESA-N 0.000 description 1
- IJMIYSXHHOKJEZ-JAMMHHFISA-N C[C@@H](CN(C1)C(OC(C)(C)C)=O)OC1C(O)=O Chemical compound C[C@@H](CN(C1)C(OC(C)(C)C)=O)OC1C(O)=O IJMIYSXHHOKJEZ-JAMMHHFISA-N 0.000 description 1
- BOWHGCGFACIASY-NTSWFWBYSA-N C[C@@H](CN([C@H](CBr)C1)C(O)=O)N1C(O)=O Chemical compound C[C@@H](CN([C@H](CBr)C1)C(O)=O)N1C(O)=O BOWHGCGFACIASY-NTSWFWBYSA-N 0.000 description 1
- PPPRHMMOYAZNNJ-HOCLYGCPSA-N C[C@@H]1N(Cc2cnc(NC(C)=O)[s]2)C[C@@H](COc2cc(C)nc(C)c2)NC1 Chemical compound C[C@@H]1N(Cc2cnc(NC(C)=O)[s]2)C[C@@H](COc2cc(C)nc(C)c2)NC1 PPPRHMMOYAZNNJ-HOCLYGCPSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 101000585728 Homo sapiens Protein O-GlcNAcase Proteins 0.000 description 1
- 101000652482 Homo sapiens TBC1 domain family member 8 Proteins 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- SJFZPUZJNLDCGE-UHFFFAOYSA-N N-[5-(1-chloroethyl)-1,3-thiazol-2-yl]acetamide Chemical compound CC(Cl)c1cnc(NC(C)=O)s1 SJFZPUZJNLDCGE-UHFFFAOYSA-N 0.000 description 1
- CKCNTRWEWCYWRW-GXFFZTMASA-N N-[5-[(1S)-1-[(2R)-2-[(5-fluoropyrimidin-2-yl)methyl]morpholin-4-yl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C[C@H]1OCCN(C1)[C@@H](C)C1=CN=C(S1)NC(C)=O CKCNTRWEWCYWRW-GXFFZTMASA-N 0.000 description 1
- CKCNTRWEWCYWRW-JLOHTSLTSA-N N-[5-[1-[(2R)-2-[(5-fluoropyrimidin-2-yl)methyl]morpholin-4-yl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C[C@H]1OCCN(C1)C(C)C1=CN=C(S1)NC(C)=O CKCNTRWEWCYWRW-JLOHTSLTSA-N 0.000 description 1
- AHWJLTMIBBXTPW-HZMBPMFUSA-N N-[5-[[(2R)-2-[(1R)-1-(5-fluoropyrimidin-2-yl)ethyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)[C@@H](C)[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O AHWJLTMIBBXTPW-HZMBPMFUSA-N 0.000 description 1
- AHWJLTMIBBXTPW-YGRLFVJLSA-N N-[5-[[(2R)-2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)[C@H](C)[C@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O AHWJLTMIBBXTPW-YGRLFVJLSA-N 0.000 description 1
- IOUZZBWPHFMTDB-QGZVFWFLSA-N N-[5-[[(2R)-2-[(2,6-dimethylpyridin-4-yl)methyl]-1,4-oxazepan-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC(=CC(=C1)C[C@H]1OCCCN(C1)CC1=CN=C(S1)NC(C)=O)C IOUZZBWPHFMTDB-QGZVFWFLSA-N 0.000 description 1
- XVFLCRIZIQNQBZ-OAHLLOKOSA-N N-[5-[[(2R)-2-[(2-methoxypyridin-4-yl)methyl]-1,4-oxazepan-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound COC1=NC=CC(=C1)C[C@H]1OCCCN(C1)CC1=CN=C(S1)NC(C)=O XVFLCRIZIQNQBZ-OAHLLOKOSA-N 0.000 description 1
- LMPRQFAAVNSRFO-ZWNOBZJWSA-N N-[5-[[(2R,5R)-2-[(5-fluoropyrimidin-2-yl)methyl]-5-methylmorpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C[C@H]1OC[C@H](N(C1)CC1=CN=C(S1)NC(C)=O)C LMPRQFAAVNSRFO-ZWNOBZJWSA-N 0.000 description 1
- IVJSBPRSSWGPAJ-SWLSCSKDSA-N N-[5-[[(2R,5S)-2-[(2-methoxypyridin-4-yl)methyl]-5-methylmorpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound COC1=NC=CC(=C1)C[C@H]1OC[C@@H](N(C1)CC1=CN=C(S1)NC(C)=O)C IVJSBPRSSWGPAJ-SWLSCSKDSA-N 0.000 description 1
- CBXPADGVWMYEMV-GXFFZTMASA-N N-[5-[[(2R,6S)-2-[(5-fluoropyrimidin-2-yl)methyl]-6-methylmorpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C[C@H]1O[C@H](CN(C1)CC1=CN=C(S1)NC(C)=O)C CBXPADGVWMYEMV-GXFFZTMASA-N 0.000 description 1
- XVFLCRIZIQNQBZ-HNNXBMFYSA-N N-[5-[[(2S)-2-[(2-methoxypyridin-4-yl)methyl]-1,4-oxazepan-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound COC1=NC=CC(=C1)C[C@@H]1OCCCN(C1)CC1=CN=C(S1)NC(C)=O XVFLCRIZIQNQBZ-HNNXBMFYSA-N 0.000 description 1
- DHOCHFDQUZRPKM-LBPRGKRZSA-N N-[5-[[(2S)-2-[(5-fluoropyrimidin-2-yl)methyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C[C@@H]1OCCN(C1)CC1=CN=C(S1)NC(C)=O DHOCHFDQUZRPKM-LBPRGKRZSA-N 0.000 description 1
- MLDYEFQJNAWOIV-KBXCAEBGSA-N N-[5-[[(2S,5R)-4-acetyl-2-methyl-5-[(2-methylpyridin-4-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C(C)(=O)N1C[C@@H](N(C[C@H]1CC1=CC(=NC=C1)C)CC1=CN=C(S1)NC(C)=O)C MLDYEFQJNAWOIV-KBXCAEBGSA-N 0.000 description 1
- UCFPMGSHJQYLIS-KBXCAEBGSA-N N-[5-[[(2S,5R)-4-acetyl-2-methyl-5-[(6-methylpyridin-3-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C(C)(=O)N1C[C@@H](N(C[C@H]1CC=1C=NC(=CC=1)C)CC1=CN=C(S1)NC(C)=O)C UCFPMGSHJQYLIS-KBXCAEBGSA-N 0.000 description 1
- IUMNAKQVKGVOTN-XHDPSFHLSA-N N-[5-[[(2S,5R)-4-acetyl-5-[(5-fluoropyrimidin-2-yl)methyl]-2-methylpiperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C(C)(=O)N1C[C@@H](N(C[C@H]1CC1=NC=C(C=N1)F)CC1=CN=C(S1)NC(C)=O)C IUMNAKQVKGVOTN-XHDPSFHLSA-N 0.000 description 1
- XTQWTXUAORLKFL-YJBOKZPZSA-N N-[5-[[(2S,5S)-4-acetyl-5-[(2,6-dimethylpyridin-4-yl)oxymethyl]-2-methylpiperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C(C)(=O)N1C[C@@H](N(C[C@H]1COC1=CC(=NC(=C1)C)C)CC1=CN=C(S1)NC(C)=O)C XTQWTXUAORLKFL-YJBOKZPZSA-N 0.000 description 1
- PQDXGGJQZXJUGX-QGZVFWFLSA-N N-[5-[[(3R)-3-[(2,6-dimethylpyridin-4-yl)methyl]-4-methylpiperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC(=CC(=C1)C[C@@H]1CN(CCN1C)CC1=CN=C(S1)NC(C)=O)C PQDXGGJQZXJUGX-QGZVFWFLSA-N 0.000 description 1
- SZZAVXYBHLJLED-PKLMIRHRSA-N N-[5-[[(3R)-3-[(2,6-dimethylpyridin-4-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide hydrochloride Chemical compound Cl.CC1=NC(=CC(=C1)C[C@@H]1CN(CCN1)CC1=CN=C(S1)NC(C)=O)C SZZAVXYBHLJLED-PKLMIRHRSA-N 0.000 description 1
- KIUWVFORSLTVSL-CQSZACIVSA-N N-[5-[[(3R)-3-[(4-fluoro-3-methoxyphenyl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC1=C(C=C(C[C@@H]2CN(CCN2)CC2=CN=C(S2)NC(C)=O)C=C1)OC KIUWVFORSLTVSL-CQSZACIVSA-N 0.000 description 1
- ANMJKGILRRDWIX-MRXNPFEDSA-N N-[5-[[(3R)-4-methyl-3-[(2-methylpyridin-4-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CN1[C@@H](CN(CC1)CC1=CN=C(S1)NC(C)=O)CC1=CC(=NC=C1)C ANMJKGILRRDWIX-MRXNPFEDSA-N 0.000 description 1
- QCRZVJZLBOSOPR-MRXNPFEDSA-N N-[5-[[(3R)-4-methyl-3-[(6-methylpyridin-3-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CN1[C@@H](CN(CC1)CC1=CN=C(S1)NC(C)=O)CC=1C=NC(=CC=1)C QCRZVJZLBOSOPR-MRXNPFEDSA-N 0.000 description 1
- MIGMUBJKKNTZIN-AWEZNQCLSA-N N-[5-[[(3S)-3-[(2-methoxypyridin-4-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound COC1=NC=CC(=C1)C[C@H]1CN(CCN1)CC1=CN=C(S1)NC(C)=O MIGMUBJKKNTZIN-AWEZNQCLSA-N 0.000 description 1
- KIUWVFORSLTVSL-AWEZNQCLSA-N N-[5-[[(3S)-3-[(4-fluoro-3-methoxyphenyl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC1=C(C=C(C[C@H]2CN(CCN2)CC2=CN=C(S2)NC(C)=O)C=C1)OC KIUWVFORSLTVSL-AWEZNQCLSA-N 0.000 description 1
- ZKFDBHAIURQXMJ-LBPRGKRZSA-N N-[5-[[(3S)-3-[(5-fluoropyrimidin-2-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C[C@H]1CN(CCN1)CC1=CN=C(S1)NC(C)=O ZKFDBHAIURQXMJ-LBPRGKRZSA-N 0.000 description 1
- QCRZVJZLBOSOPR-INIZCTEOSA-N N-[5-[[(3S)-4-methyl-3-[(6-methylpyridin-3-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CN1[C@H](CN(CC1)CC1=CN=C(S1)NC(C)=O)CC=1C=NC(=CC=1)C QCRZVJZLBOSOPR-INIZCTEOSA-N 0.000 description 1
- PAZLNWLYKGESLA-QGZVFWFLSA-N N-[5-[[(6R)-6-[(2,6-dimethylpyridin-4-yl)methyl]-1,4-oxazepan-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC(=CC(=C1)C[C@@H]1CN(CCOC1)CC1=CN=C(S1)NC(C)=O)C PAZLNWLYKGESLA-QGZVFWFLSA-N 0.000 description 1
- MENIMQQQHRJRHW-OAHLLOKOSA-N N-[5-[[(6R)-6-[(2-methoxypyridin-4-yl)methyl]-1,4-oxazepan-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound COC1=NC=CC(=C1)C[C@@H]1CN(CCOC1)CC1=CN=C(S1)NC(C)=O MENIMQQQHRJRHW-OAHLLOKOSA-N 0.000 description 1
- ATWRQLOWQHBYHG-GFCCVEGCSA-N N-[5-[[(6R)-6-[(5-fluoropyrimidin-2-yl)methyl]-1,4-oxazepan-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C[C@@H]1CN(CCOC1)CC1=CN=C(S1)NC(C)=O ATWRQLOWQHBYHG-GFCCVEGCSA-N 0.000 description 1
- PAZLNWLYKGESLA-KRWDZBQOSA-N N-[5-[[(6S)-6-[(2,6-dimethylpyridin-4-yl)methyl]-1,4-oxazepan-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC(=CC(=C1)C[C@H]1CN(CCOC1)CC1=CN=C(S1)NC(C)=O)C PAZLNWLYKGESLA-KRWDZBQOSA-N 0.000 description 1
- MENIMQQQHRJRHW-HNNXBMFYSA-N N-[5-[[(6S)-6-[(2-methoxypyridin-4-yl)methyl]-1,4-oxazepan-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound COC1=NC=CC(=C1)C[C@H]1CN(CCOC1)CC1=CN=C(S1)NC(C)=O MENIMQQQHRJRHW-HNNXBMFYSA-N 0.000 description 1
- ATWRQLOWQHBYHG-LBPRGKRZSA-N N-[5-[[(6S)-6-[(5-fluoropyrimidin-2-yl)methyl]-1,4-oxazepan-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C[C@H]1CN(CCOC1)CC1=CN=C(S1)NC(C)=O ATWRQLOWQHBYHG-LBPRGKRZSA-N 0.000 description 1
- AHWJLTMIBBXTPW-UHFFFAOYSA-N N-[5-[[2-[1-(5-fluoropyrimidin-2-yl)ethyl]morpholin-4-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)C(C)C1OCCN(C1)CC1=CN=C(S1)NC(C)=O AHWJLTMIBBXTPW-UHFFFAOYSA-N 0.000 description 1
- GYHZBKKUPVOCIG-UHFFFAOYSA-N N-[5-[[3-[(2,6-dimethylpyridin-4-yl)methyl]-4-methyl-1,4-diazepan-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC(=CC(=C1)CC1CN(CCCN1C)CC1=CN=C(S1)NC(C)=O)C GYHZBKKUPVOCIG-UHFFFAOYSA-N 0.000 description 1
- FVABMQZKPFMYCD-UHFFFAOYSA-N N-[5-[[3-[(2-methoxypyridin-4-yl)methyl]-1,4-diazepan-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound COC1=NC=CC(=C1)CC1CN(CCCN1)CC1=CN=C(S1)NC(C)=O FVABMQZKPFMYCD-UHFFFAOYSA-N 0.000 description 1
- RGDNULMAFMHWMF-UHFFFAOYSA-N N-[5-[[3-[(2-methoxypyridin-4-yl)methyl]-4-methylpiperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound COC1=NC=CC(=C1)CC1CN(CCN1C)CC1=CN=C(S1)NC(C)=O RGDNULMAFMHWMF-UHFFFAOYSA-N 0.000 description 1
- IIBYAQYCSUIRJK-UHFFFAOYSA-N N-[5-[[3-[(2-methylpyridin-4-yl)methyl]-1,4-diazepan-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=NC=CC(=C1)CC1CN(CCCN1)CC1=CN=C(S1)NC(C)=O IIBYAQYCSUIRJK-UHFFFAOYSA-N 0.000 description 1
- OJJIKCBNNKYZPA-UHFFFAOYSA-N N-[5-[[3-[(3-fluoro-2-methoxypyridin-4-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C(=NC=CC=1CC1CN(CCN1)CC1=CN=C(S1)NC(C)=O)OC OJJIKCBNNKYZPA-UHFFFAOYSA-N 0.000 description 1
- GPAQDAUYJFOGSF-UHFFFAOYSA-N N-[5-[[3-[(5-fluoropyrimidin-2-yl)methyl]-1,4-diazepan-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)CC1CN(CCCN1)CC1=CN=C(S1)NC(C)=O GPAQDAUYJFOGSF-UHFFFAOYSA-N 0.000 description 1
- SIMKWEPSDGZWOU-UHFFFAOYSA-N N-[5-[[3-[(5-fluoropyrimidin-2-yl)methyl]-4-methyl-1,4-diazepan-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=NC(=NC=1)CC1CN(CCCN1C)CC1=CN=C(S1)NC(C)=O SIMKWEPSDGZWOU-UHFFFAOYSA-N 0.000 description 1
- NNKUCWYRFQZUCQ-UHFFFAOYSA-N N-[5-[[3-[(6-methylpyridin-3-yl)methyl]piperazin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC1=CC=C(C=N1)CC1CN(CCN1)CC1=CN=C(S1)NC(C)=O NNKUCWYRFQZUCQ-UHFFFAOYSA-N 0.000 description 1
- KWROYZOYDPDTGC-UHFFFAOYSA-N N-[5-[[4-acetyl-3-[(2-methoxypyridin-4-yl)methyl]-1,4-diazepan-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C(C)(=O)N1C(CN(CCC1)CC1=CN=C(S1)NC(C)=O)CC1=CC(=NC=C1)OC KWROYZOYDPDTGC-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 230000006271 O-GlcNAcylation Effects 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100030302 TBC1 domain family member 8 Human genes 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 101150012828 UPC2 gene Proteins 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- OJADDPKDAQXHHI-UHFFFAOYSA-N acetamide;hydron;bromide Chemical compound Br.CC(N)=O OJADDPKDAQXHHI-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- CJVBYZDTBYFUBB-UHFFFAOYSA-N benzyl 2-[(5-fluoropyrimidin-2-yl)methyl]-1,4-diazepane-1-carboxylate hydrochloride Chemical compound Cl.FC=1C=NC(=NC=1)CC1N(CCCNC1)C(=O)OCC1=CC=CC=C1 CJVBYZDTBYFUBB-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- SQMFULTZZQBFBM-UHFFFAOYSA-N bis(trimethylsilyl)silyl-trimethylsilane Chemical compound C[Si](C)(C)[SiH]([Si](C)(C)C)[Si](C)(C)C SQMFULTZZQBFBM-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 102000046319 human OGA Human genes 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 1
- 229910001486 lithium perchlorate Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- LPEKGGXMPWTOCB-UHFFFAOYSA-N methyl 2-hydroxypropionate Chemical compound COC(=O)C(C)O LPEKGGXMPWTOCB-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- WXPLRSVMGRAIGW-UHFFFAOYSA-N n-(1,3-thiazol-2-yl)acetamide Chemical compound CC(=O)NC1=NC=CS1 WXPLRSVMGRAIGW-UHFFFAOYSA-N 0.000 description 1
- SFMJNHNUOVADRW-UHFFFAOYSA-N n-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide Chemical compound C1=C(NC(=O)C=C)C(C)=CC=C1N1C(=O)C=CC2=C1C1=CC(C=3C=CC(NS(C)(=O)=O)=CC=3)=CC=C1N=C2 SFMJNHNUOVADRW-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000012740 non-selective inhibitor Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N p-hydroxybenzoic acid propyl ester Natural products CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- JSSXHAMIXJGYCS-UHFFFAOYSA-N piperazin-4-ium-2-carboxylate Chemical compound OC(=O)C1CNCCN1 JSSXHAMIXJGYCS-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- OBJOQVLWWLTNLQ-RKDXNWHRSA-N tert-butyl (2S,5R)-2-(bromomethyl)-5-methylmorpholine-4-carboxylate Chemical compound BrC[C@@H]1CN([C@@H](CO1)C)C(=O)OC(C)(C)C OBJOQVLWWLTNLQ-RKDXNWHRSA-N 0.000 description 1
- RLXCSEPIBOWMOJ-MRVPVSSYSA-N tert-butyl (2s)-2-(bromomethyl)morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCO[C@H](CBr)C1 RLXCSEPIBOWMOJ-MRVPVSSYSA-N 0.000 description 1
- JMEYIVSMANQBPF-UHFFFAOYSA-N tert-butyl 2-(1-bromoethyl)morpholine-4-carboxylate Chemical compound BrC(C)C1CN(CCO1)C(=O)OC(C)(C)C JMEYIVSMANQBPF-UHFFFAOYSA-N 0.000 description 1
- WBAQNCJUTMXJTK-UHFFFAOYSA-N tert-butyl 2-(hydroxymethyl)-1,4-oxazepane-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCOC(CO)C1 WBAQNCJUTMXJTK-UHFFFAOYSA-N 0.000 description 1
- WXVUXCIDVNJQHH-UHFFFAOYSA-N tert-butyl 2-[(2,6-dimethylpyridin-4-yl)methyl]piperazine-1-carboxylate Chemical compound CC1=NC(=CC(=C1)CC1N(CCNC1)C(=O)OC(C)(C)C)C WXVUXCIDVNJQHH-UHFFFAOYSA-N 0.000 description 1
- VKCJRMHSOMRAIH-UHFFFAOYSA-N tert-butyl 2-[(2-methoxypyridin-4-yl)methyl]piperazine-1-carboxylate Chemical compound COC1=NC=CC(=C1)CC1N(CCNC1)C(=O)OC(C)(C)C VKCJRMHSOMRAIH-UHFFFAOYSA-N 0.000 description 1
- LJUFWUIUVLJYDF-UHFFFAOYSA-N tert-butyl 2-acetylmorpholine-4-carboxylate Chemical compound CC(=O)C1CN(C(=O)OC(C)(C)C)CCO1 LJUFWUIUVLJYDF-UHFFFAOYSA-N 0.000 description 1
- BVJXORMQZNDTOW-UHFFFAOYSA-N tert-butyl 6-(bromomethyl)-1,4-oxazepane-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOCC(CBr)C1 BVJXORMQZNDTOW-UHFFFAOYSA-N 0.000 description 1
- SLJSFXUOECCLPA-UHFFFAOYSA-N tert-butyl 6-(hydroxymethyl)-1,4-oxazepane-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOCC(CO)C1 SLJSFXUOECCLPA-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000001166 thiolanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- SCHZCUMIENIQMY-UHFFFAOYSA-N tris(trimethylsilyl)silicon Chemical compound C[Si](C)(C)[Si]([Si](C)(C)C)[Si](C)(C)C SCHZCUMIENIQMY-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
本出願は、米国特許法第35条§119(e)に基づいて、出願日2018年12月5日に出願された米国仮出願第62/775,558号の出願日の優先権を主張し、その全内容は参照により本明細書に援用される。
Arは、任意置換の5~10員アリールまたは任意置換の5~10員ヘテロアリールであり、Arは、mとpの合計が1である場合、1~4個の窒素原子を有する9員二環式ヘテロアリールではなく;
Wは、Oまたは-NRdであり;
Xは、-CR2R2、-(CR2R2)2、-(CR2R2)O-または-O(CR2R2)-であり;
Y1及びY2は、それぞれCRcまたはNであり、Y1またはY2の少なくとも一方はNであり;
Zは、-CR2R2、-C(=O)、-(CR2R2)2、または-CH2C(=O)であり;
Rcは、-H、ハロ、-C1-C4アルキル、または-C1-C4ハロアルキルであり、
Rdは、-H、C1-C4アルキル、C1-C4ハロアルキル、または-C(=O)C1-C4アルキルであり;
mは、1または2であり;
mとpの合計が3でない限り、pは0または1であり;
nは、0または1~9の整数であり;
nが0以外である場合、R1は、それぞれ独立して、ハロ、-C1-C4アルキル、-C1-C4ハロアルキル、または-C1-C4アルコキシであり;
R2は、それぞれ独立して、-H、ハロ、-C1-C4アルキル、-C1-C4ハロアルキル、-C3-C10シクロアルキル、または-C3-C10ハロシクロアルキルであり;
あるいは、2つのR2が、それらが結合している炭素原子と一緒になって、-C3-C10シクロアルキルを形成し;
R3は、-Hまたは-C1-C4アルキルであり;そして、
R4は、-H、-C1-C4アルキル、-C1-C4ハロアルキル、または-C3-C6シクロアルキルであり;
あるいは、R3及びR4は、それらの介在原子と一緒になって、任意置換の5~7員ヘテロシクリルを形成する。
式中、
Ar上のC1-C4アルキル基置換基は、-CN、-NO2、-ORz、-NRxRy、-S(O)iRx、-NRxS(O)iRy、-S(O)iNRxRy、-C(=O)ORx、-OC(=O)ORx、-C(=S)ORx、-O(C=S)Rx、-C(=O)NRxRy、-NRxC(=O)Ry、-C(=S)NRxRy-NRxC(=S)Ry、-NRx(C=O)ORy、-O(C=O)NRxRy、-NRx(C=S)ORy、-O(C=S)NRxRy、-NRx(C=O)NRxRy、-NRx(C=S)NRxRy、-C(=S)Rx、及び-C(=O)Ry、C3-C6シクロアルキル(-CH3、ハロメチル、ハロ、メトキシ及びハロメトキシから選択される1つ以上の基で任意に置換される)、単環式ヘテロアリール(-CH3、ハロメチル、ハロ、メトキシまたはハロメトキシから選択される1つ以上の基で任意に置換される)及びフェニル(-CH3、ハロメチル、ハロ、メトキシ及びハロメトキシから選択される1つ以上の基で任意に置換される)で任意に置換され;
Ar上のC3-C6シクロアルキル、C3-C6ヘテロシクリル、フェニル及び単環式ヘテロアリール基置換基は、任意選択で、かつ独立して、C1-C4アルキル、C1-C4ハロアルキル、ハロ、-CN、-NO2、-ORz、-NRxRy、-S(O)iRx、-NRxS(O)iRy、-S(O)iNRxRy、-C(=O)ORx、-OC(=O)ORx、-C(=S)ORx、-O(C=S)Ry、-C(=O)NRxRy、-NRxC(=O)Ry、-C(=S)NRxRy、-NRxC(=S)Ry、-NRx(C=O)ORy、-O(C=O)NRxRy、-NRx(C=S)ORy、-O(C=S)NRxRy、-NRx(C=O)NRxRy、-NRx(C=S)NRxRy、-C(=S)Rx、及び-C(=O)Rxで置換され;
各Rx及び各Ryは、独立して、-H、C1-C4アルキル、またはC3-C8シクロアルキルであり;RxまたはRyで表されるC1-C4アルキルまたはC3-C8シクロアルキルは、ハロ、ヒドロキシル、C3-C6シクロアルキル及びフェニル(-CH3、ハロメチル、ハロ、メトキシまたはハロメトキシから選択される1つ以上の基で任意に置換される)から選択される1つ以上の置換基で任意に置換され;
Rzは、-H、C1-C4アルキル、C1-C4アルコキシ、C3-C8シクロアルキル、またはC3-C8ヘテロシクリルであり;Rzで表されるC1-C4アルキルまたはC3-C8シクロアルキル基は、-CN、ハロ、ヒドロキシル、C1-C4アルキル、C1-C4アルコキシ、C3-C6シクロアルキル、及びフェニル(-CH3、ハロメチル、ハロ、メトキシ及びハロメトキシから選択される1つ以上の基で任意に置換される)から選択される1つ以上の置換基で任意に置換され;そして
iは、0、1、または2である。
(R)-N-(5-((2-((5-フルオロピリミジン-2-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((2-メトキシピリジン-4-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((2-メトキシ-3-メチルピリジン-4-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-(4-フルオロ-3-メトキシベンジル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((2-メトキシピリミジン-4-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((6-メトキシピリミジン-4-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((2-(2,2,2-トリフルオロエトキシ)ピリジン-4-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((2-エトキシピリジン-4-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((2-イソプロポキシピリジン-4-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((2-(ジフルオロメチル)ピリジン-4-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((2-メチルピリミジン-4-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((3-フルオロ-2-メトキシピリジン-4-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((5-メチルピリジン-2-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((2-(ジフルオロメトキシ)ピリジン-4-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((5-フルオロ-4-メチルピリジン-2-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((6-メチルピリジン-3-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((2-メチルピリジン-4-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((2,6-ジメチルピリジン-4-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
N-(5-((R)-1-((R)-2-((5-フルオロピリミジン-2-イル)メチル)モルホリノ)エチル)チアゾール-2-イル)アセトアミド;
N-(5-((S)-1-((R)-2-((5-フルオロピリミジン-2-イル)メチル)モルホリノ)エチル)チアゾール-2-イル)アセトアミド;
N-(5-(((R)-2-((R)-1-(5-フルオロピリミジン-2-イル)エチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((R)-2-((S)-1-(5-フルオロピリミジン-2-イル)エチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((S)-2-((S)-1-(5-フルオロピリミジン-2-イル)エチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((S)-2-((R)-1-(5-フルオロピリミジン-2-イル)エチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2R,5S)-2-((5-フルオロピリミジン-2-イル)メチル)-5-メチルモルホリノ)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5S)-2-((5-フルオロピリミジン-2-イル)メチル)-5-メチルモルホリノ)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2R,5S)-2-((2,6-ジメチルピリジン-4-イル)メチル)-5-メチルモルホリノ)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2R,5S)-5-メチル-2-((2-メチルピリジン-4-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2R,5S)-5-メチル-2-((6-メチルピリジン-3-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((cis)-2-((5-フルオロピリミジン-2-イル)メチル)-6-メチルモルホリノ)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2R,6S)-2-((5-フルオロピリミジン-2-イル)メチル)-6-メチルモルホリノ)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,6R)-2-((5-フルオロピリミジン-2-イル)メチル)-6-メチルモルホリノ)メチル)チアゾール-2-イル)アセトアミド;
N-(5-((2-((2,6-ジメチルピリジン-4-イル)メチル)-1,4-オキサゼパン-4-イル)メチル)チアゾール-2-イル)アセトアミド;
(S)-N-(5-((2-((2,6-ジメチルピリジン-4-イル)メチル)-1,4-オキサゼパン-4-イル)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((2,6-ジメチルピリジン-4-イル)メチル)-1,4-オキサゼパン-4-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-((2-((5-フルオロピリミジン-2-イル)メチル)-1,4-オキサゼパン-4-イル)メチル)チアゾール-2-イル)アセトアミド;
(S)-N-(5-((2-((5-フルオロピリミジン-2-イル)メチル)-1,4-オキサゼパン-4-イル)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((5-フルオロピリミジン-2-イル)メチル)-1,4-オキサゼパン-4-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-((2-((2-メトキシピリジン-4-イル)メチル)-1,4-オキサゼパン-4-イル)メチル)チアゾール-2-イル)アセトアミド;
(S)-N-(5-((2-((2-メトキシピリジン-4-イル)メチル)-1,4-オキサゼパン-4-イル)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((2-((2-メトキシピリジン-4-イル)メチル)-1,4-オキサゼパン-4-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-((6-((2,6-ジメチルピリジン-4-イル)メチル)-1,4-オキサゼパン-4-イル)メチル)チアゾール-2-イル)アセトアミド;
(S)-N-(5-((6-((2,6-ジメチルピリジン-4-イル)メチル)-1,4-オキサゼパン-4-イル)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((6-((2,6-ジメチルピリジン-4-イル)メチル)-1,4-オキサゼパン-4-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-((6-((5-フルオロピリミジン-2-イル)メチル)-1,4-オキサゼパン-4-イル)メチル)チアゾール-2-イル)アセトアミド;
(S)-N-(5-((6-((5-フルオロピリミジン-2-イル)メチル)-1,4-オキサゼパン-4-イル)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((6-((5-フルオロピリミジン-2-イル)メチル)-1,4-オキサゼパン-4-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-((6-((2-メトキシピリジン-4-イル)メチル)-1,4-オキサゼパン-4-イル)メチル)チアゾール-2-イル)アセトアミド;
(S)-N-(5-((6-((2-メトキシピリジン-4-イル)メチル)-1,4-オキサゼパン-4-イル)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((6-((2-メトキシピリジン-4-イル)メチル)-1,4-オキサゼパン-4-イル)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(4-フルオロ-5-((2-((6-メチルピリジン-3-イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
N-(4-フルオロ-5-(((2R,5S)-5-メチル-2-((6-メチルピリジン-3イル)メチル)モルホリノ)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5R)-2-メチル-5-((2-メチルピリジン-4-イル)メチル)ピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5R)-2,4-ジメチル-5-((2-メチルピリジン-4-イル)メチル)ピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5R)-4-エチル-2-メチル-5-((2-メチルピリジン-4-イル)メチル)ピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5R)-5-((5-フルオロピリミジン-2-イル)メチル)-2-メチルピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5R)-5-((5-フルオロピリミジン-2-イル)メチル)-2,4-ジメチルピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5R)-5-((2,6-ジメチルピリジン-4-イル)メチル)-2-メチルピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5R)-2-メチル-5-((6-メチルピリジン-3-イル)メチル)ピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5R)-5-((2,6-ジメチルピリジン-4-イル)メチル)-2,4-ジメチルピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5R)-2,4-ジメチル-5-((6-メチルピリジン-3-イル)メチル)ピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5R)-4-エチル-2-メチル-5-((6-メチルピリジン-3-イル)メチル)ピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5R)-5-((2,6-ジメチルピリミジン-4-イル)メチル)-2-メチルピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5R)-5-((2-メトキシピリジン-4-イル)メチル)-2-メチルピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5R)-5-((2,6-ジメチルピリミジン-4-イル)メチル)-2,4-ジメチルピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5R)-5-((2-メトキシピリジン-4-イル)メチル)-2,4-ジメチルピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-((3-((5-フルオロピリミジン-2-イル)メチル)ピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-((3-((2-メトキシピリジン-4-イル)メチル)ピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5S)-5-(((2,6-ジメチルピリジン-4-イル)オキシ)メチル)-2-メチルピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5S)-5-(((2,6-ジメチルピリジン-4-イル)オキシ)メチル)-2,4-ジメチルピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5S)-2-(((2,6-ジメチルピリジン-4-イル)オキシ)メチル)-5メチルモルホリノ)メチル)チアゾール-2-イル)アセトアミド;
N-(5-(((2S,5S)-2-(((2,6-ジメチルピリジン-4-イル)オキシ)メチル)-5メチルモルホリノ)メチル)チアゾール-2-イル)アセトアミド;
(S)-N-(5-((3-((2,6-ジメチルピリジン-4-イル)メチル)ピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド塩酸塩;
(S)-N-(5-((3-((2,6-ジメチルピリジン-4-イル)メチル)-4-メチルピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
N-(5-((3-(4-フルオロ-3-メトキシベンジル)ピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
(R)-N-(5-((3-((2-メチルピリジン-4-イル)メチル)ピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
(S)-N-(5-((3-((2-メチルピリジン-4-イル)メチル)ピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;及び
(S)-N-(5-((4-メチル-3-((2-メチルピリジン-4-イル)メチル)ピペラジン-1-イル)メチル)チアゾール-2-イル)アセトアミド;
またはその薬学的に許容される塩。
Teledyne ISCO Combiflash RFまたはELSD精製システムを備えたGrace Reveleris X2のいずれかを使用して、20~40uM(粒子サイズ)、250~400メッシュ、または400~632メッシュのシリカゲルを使用して、シリカゲルクロマトグラフィーを実施した。
酸性HPLC:2.75mL/4L TFA水溶液(溶媒A)及び2.5mL/4L TFAアセトニトリル(溶媒B)で溶出するUltimate C18 3.0×50mm、3umカラムを備えたShimadzu 20A装置を使用して、以下の方法により実施した:
方法A:以下の溶出勾配を使用 1.2ml/分の流速で、0%~60%(溶媒B)で6分間、60%で2分間保持。波長:UV220nm、215nm及び254nm。
方法B:以下の溶出勾配を使用 1.2ml/分の流速で、10%~80%(溶媒B)で6分間、60%で2分間保持。波長:UV220nm、215nm及び254nm。
方法C:以下の溶出勾配を使用 1.2ml/分の流速で、30%~90%(溶媒B)で6分間、60%で2分間保持。波長:UV220nm、215nm及び254nm。
塩基性HPLC: 2mL/4L NH3H2O水溶液(溶媒A)及びアセトニトリル(溶媒B)で溶出するXbrige Shield RP-18、5um、2.1×50mmカラムを備えたShimadzu 20A装置を使用して、以下の方法により実施した:
方法D:以下の溶出勾配を使用 1.2ml/分の流速で、0%~60%(溶媒B)で4.0分間、60%で2分間保持。
方法E:以下の溶出勾配を使用 1.2ml/分の流速で、10%~80%(溶媒B)で4.0分間、60%で2分間保持。
方法F:以下の溶出勾配を使用 1.2ml/分の流速で、30%~90%(溶媒B)で4.0分間、60%で2分間保持。
酸性LCMS:1.5mL/4L TFA水溶液(溶媒A)及び0.75mL/4L TFA アセトニトリル溶液(溶媒B)で溶出するC18カラム(2.1mm×30mm、3.0mmまたは2.1mm×50mm、C18、1.7um)を備えたShimadzu 2010シリーズ、Shimadzu 020シリーズ、またはWaters Acquity UPLC BEH.(MSイオン化:ESI)装置で、以下の方法を使用して実施した:
1.5分間の方法:
一般的な方法:以下の溶出勾配を使用 1.5ml/分の流速で、5%~95%(溶媒B)で0.7分間、95%で0.4分間保持。波長:UV220nm及び254nm。
方法A:以下の溶出勾配を使用 1.2ml/分の流速で、0%~60%(溶媒B)で0.9分間、60%で0.6分間保持。波長:UV220nm及び254nm。
方法B:以下の溶出勾配を使用 1.2ml/分の流速で、10%~80%(溶媒B)で0.9分間、60%で0.6分間保持。波長:UV220nm及び254nm。
方法C:以下の溶出勾配を使用 1.2ml/分の流速で、30%~90%(溶媒B)で0.9分間、60%で0.6分間保持。波長:UV220nm及び254nm。
初期条件、溶媒A-95%:溶媒B-5%;0.0~0.1分は、初期値を保持;0.1~3.25分は、溶媒A-5%:溶媒B-95%へ直線傾斜;3.25~3.5分は、溶媒A-5%:溶媒B-95%を保持;ダイオードアレイ/MS検出。
方法A:以下の溶出勾配を使用 0.8ml/分の流速で、0%~60%(溶媒B)で3分間、60%で0.5分間保持。波長:UV220nm及び254nm。
方法B:以下の溶出勾配を使用 0.8ml/分の流速で、10%~80%(溶媒B)で3分間、60%で0.5分間保持。波長:UV220nm及び254nm。
方法C:以下の溶出勾配を使用 0.8ml/分の流速で、30%~90%(溶媒B)で3分間、60%で0.5分間保持。波長:UV220nm及び254nm。
方法A:以下の溶出勾配を使用 0.8ml/分の流速で、0%~60%(溶媒B)で6分間、60%で0.5分間保持。波長:UV220nm及び254nm。
方法B:以下の溶出勾配を使用 0.8ml/分の流速で、10%~80%(溶媒B)で6分間、60%で0.5分間保持。波長:UV220nm及び254nm。
方法C:以下の溶出勾配を使用 0.8ml/分の流速で、30%~900%(溶媒B)で6分間、60%で0.5分間保持。波長:UV220nm及び254nm。
3分間の方法:
方法A:以下の溶出勾配を使用 1ml/分の流速で、0%~60%(溶媒B)で2分間、60%で0.48分間保持。波長:UV220nm及び254nm。
方法B:以下の溶出勾配を使用 1ml/分の流速で、10%~80%(溶媒B)で2分間、60%で0.48分間保持。波長:UV220nm及び254nm。
方法C:以下の溶出勾配を使用 1ml/分の流速で、30%~90%(溶媒B)で2分間、60%で0.48分間保持。波長:UV220nm及び254nm。
初期条件、溶媒A-95%:溶媒B-5%;0.0~0.1分は、初期値を保持;0.1~3.25分は、溶媒A-5%:溶媒B-95%へ直線傾斜;3.25~3.5分は、溶媒A-5%:溶媒B-95%を保持;ダイオードアレイ/MS検出。
方法A:以下の溶出勾配を使用 0.8ml/分の流速で、0%~60%(溶媒B)で6分間、60%で0.5分間保持。波長:UV220nm及び254nm。
方法B:以下の溶出勾配を使用 0.8ml/分の流速で、10%~80%(溶媒B)で6分間、60%で0.5分間保持。波長:UV220nm及び254nm。
方法C:以下の溶出勾配を使用 0.8ml/分の流速で、30%~90%(溶媒B)で6分間、60%で0.5分間保持。波長:UV220nm及び254nm。
装置:Waters UPC2 analytical SFC(SFC-H)。カラム:ChiralCel OJ、150×4.6mm I.D.、3μm。移動相:CO2にはA、エタノール(0.05%DEA)にはB。濃度勾配:B 40%。流速:2.5mL/分。背圧:100バール。カラム温度:35℃。波長:220nm
一般的方法:分取HPLCは、220/254nm UV検出 Gilson 281自動収集を備えたGilson UV/VIS-156で実施した。
酸性条件:使用する2つの酸等級系:塩酸及びギ酸。
方法A:塩酸塩:YMC-Actus Triart C18 150×30mm×5um、勾配は、水及び対応する酸(0.05%HCl)を含む0~100%のアセトニトリルを使用した。
方法B:ギ酸:Phenomenex Synergi C18 150×30mm×4um、勾配は、水及び対応する酸(0.225%ギ酸)を含む0~100%のアセトニトリルを使用し、勾配の形状は、個々の分離について最適化した。
中性条件:Xtimate C18 150×25mm×5um、勾配は、0~100%(水(10mM NH4HCO3)-ACN)を使用し、勾配の形状は、個々の分離について最適化した。
塩基性条件:Waters Xbridge Prep OBD C18 150×30 10um、勾配は、0~100%の水(0.04%NH3H2O+10mM NH4HCO3)-アセトニトリルを使用し、勾配の形状は、個々の分離について最適化した。
使用するカラム:
酸:Waters SunFire Prep、C18 5um、OBD 19×100mm
塩基:Waters XSelect CSH Prep C18 5um OBD 19×100mm
濃度勾配特性:12分間の実行:初期条件:A-95%:B-5%;0.0~0.5分は、初期値を保持;0.5~7.5分は、A-5%から可変B-%(通常の範囲はB-40%~B-75%)への直線傾斜;7.5~8.0分は、B-%~B-95%への直線傾斜;8.0~10.0分は、A-5%:B-95%で保持;DAD/MS検出の終了;10.0~10.5分は、初期条件まで直線傾斜で下落させ、初期条件で1.5分間保持。
移動相:酸:A:0.1%トリフルオロ酢酸水溶液(v/v);移動相B:0.1%トリフルオロ酢酸のアセトニトリル溶液(v/v)。塩基:A:0.1%アンモニア水溶液(v/v);移動相B:0.1%アンモニアのアセトニトリル溶液(v/v)
装置:MGIII分取SFC(SFC-1)。カラム:ChiralCel OJ、250×30mm I.D.、5μm。移動相:CO2にはA、エタノール(0.1%NH3H2O)にはB。濃度勾配:B 50%。流速:40mL/分。背圧:100バール。カラム温度:38℃。波長:220nm。サイクル時間:約8分。
NMRスペクトルは、Bruker Avance III HD 500MHz、Bruker Avance III 500MHz、Bruker Avance III 400MHz、Varian-400 VNMRS、またはVarian-400 MRで記録した。化学シフトは、百万分率(ppm)単位で表す。結合定数(J)の単位はヘルツ(Hz)である。分割パターンは見かけの多重度を表し、s(シングル)、d(ダブル)、t(トリプレット)、dd(ダブル ダブレット)、dt(ダブル トリプレット)、dq(ダブル カルテット)、m(マルチプレット)、br(ブロード)として指定される。
ピーク1:LCMS (ESI): [M+H] 366. LCMS (ESI): [M+H] 366.
ピーク2:LCMS (ESI): [M+H] 366.
ピーク1: LCMS (ESI): [M+H] 366. 1H NMR: (500 MHz, メタノール-d4) δ 8.64 (s, 2H), 7.16 (s, 1H), 3.88 (ddd, J=1.83, 3.36, 11.29 Hz, 1H), 3.81-3.86 (m, 1H), 3.60-3.66 (m, 1H), 3.60 (d, J=1.22 Hz, 2H), 3.11-3.21 (m, 1H), 2.66-2.71 (m, 1H), 2.41-2.46 (m, 1H), 2.19 (s, 3H), 2.14-2.18 (m, 1H), 1.92 (dd, J=9.77, 11.60 Hz, 1H), 1.36 (d, J=7.33 Hz, 3H).
ピーク2: LCMS (ESI): [M+H] 366. 1H NMR: (500 MHz, メタノール-d4) δ 8.64 (s, 2H), 7.16 (s, 1H), 3.86-3.91 (m, 1H), 3.81-3.86 (m, 1H), 3.58-3.66 (m, 3H), 3.15 (dd, J=7.02, 8.24 Hz, 1H), 2.64-2.73 (m, 1H), 2.41-2.46 (m, 1H), 2.19 (s, 3H), 2.13-2.22 (m, 1H), 1.92 (dd, J=9.77, 11.60 Hz, 1H), 1.36 (d, J=7.33 Hz, 3H).
ピーク3: LCMS (ESI): [M+H] 366. 1H NMR: (500 MHz, メタノール-d4) δ 8.65 (s, 2H), 7.26 (s, 1H), 3.89-3.93 (m, 1H), 3.65-3.79 (m, 3H), 3.48 (dt, J=2.44, 11.29 Hz, 1H), 3.15-3.25 (m, 1H), 2.98-3.05 (m, 1H), 2.67 (dd, J=1.83, 10.99 Hz, 1H), 2.20 (s, 3H), 2.14-2.20 (m, 1H), 2.05 (dd, J=10.07, 11.29 Hz, 1H), 1.22 (d, J=7.33 Hz, 3H).
ピーク4: LCMS (ESI): [M+H] 366. 1H NMR: (500 MHz, メタノール-d4) δ 8.65 (s, 2H), 7.26 (s, 1H), 3.88-3.96 (m, 1H), 3.66-3.79 (m, 3H), 3.48 (dt, J=2.44, 11.29 Hz, 1H), 3.15-3.24 (m, 1H), 3.02 (d, J=10.99 Hz, 1H), 2.67 (dd, J=1.83, 11.60 Hz, 1H), 2.20 (s, 3H), 2.14-2.19 (m, 1H), 2.05 (dd, J=9.77, 10.99 Hz, 1H), 1.22 (d, J=7.33 Hz, 3H).
ピーク1: LCMS (ESI): [M+H] 366. 1H NMR: (500 MHz,メタノール-d4) δ 8.65 (s, 2H), 7.23 (s, 1H), 4.14-4.19 (m, 1H), 3.69 (s, 2H), 3.58-3.66 (m, 1H), 3.04-3.13 (m, 1H), 2.95-3.04 (m, 1H), 2.87 (d, J=11.6 Hz, 1H), 2.69-2.81 (m, 3H), 2.07-2.25 (m, 3H), 1.93 (t, J=10.7 Hz, 1H), 1.79 (t, J=10.7 Hz, 1H), 1.18 (t, J=7.3 Hz, 3H), 1.05 (d, J=6.1 Hz, 3H)
ピーク2: LCMS (ESI): [M+H] 366. 1H NMR: (500 MHz,メタノール-d4) δ 8.65 (s, 2H), 7.23 (s, 1H), 4.14-4.21 (m, 1H), 3.69 (s, 2H), 3.58-3.67 (m, 1H), 2.96-3.17 (m, 2H), 2.83-2.92 (m, 1H), 2.71-2.83 (m, 3H), 2.16-2.28 (m, 3H), 1.93 (t, J=10.7 Hz, 1H), 1.79 (t, J=10.7 Hz, 1H), 1.13-1.27 (m, 3H), 1.05 (d, J=6.1 Hz, 3H)
ピーク1: LCMS (ESI): [M+H] 351. 1H NMR (400 MHz, D2O) δ 8.65 (s, 2H), 7.30 (s, 1H), 3.70-3.80 (m, 2H), 3.24-3.26 (m, 1H), 3.00-3.02 (m, 3H), 2.87-2.95 (m, 1H), 2.76-2.84 (m, 2H), 2. 25 (s, 3H), 2.20-2.23 (m, 1H), 1.95-2.00 (m, 1H).
ピーク2: LCMS (ESI): [M+H] 351. 1H NMR (400 MHz, D2O) δ 8.65 (s, 2H), 7.30 (s, 1H), 3.70-3.80 (m, 2H), 3.24-3.26 (m, 1H), 3.00-3.02 (m, 3H), 2.87-2.95 (m, 1H), 2.76-2.84 (m, 2H), 2. 25 (s, 3H), 2.20-2.23 (m, 1H), 1.95-2.00 (m, 1H).
ピーク1: LCMS (ESI): [M+H] 351. 1H NMR (400 MHz, D2O) δ 8.65 (s, 2H), 7.30 (s, 1H), 3.70-3.80 (m, 2H), 3.24-3.26 (m, 1H), 3.00-3.02 (m, 3H), 2.87-2.95 (m, 1H), 2.76-2.84 (m, 2H), 2. 25 (s, 3H), 2.20-2.23 (m, 1H), 1.95-2.00 (m, 1H).
ピーク2: LCMS (ESI): [M+H] 351. 1H NMR (400 MHz, D2O) δ 8.65 (s, 2H), 7.30 (s, 1H), 3.70-3.80 (m, 2H), 3.24-3.26 (m, 1H), 3.00-3.02 (m, 3H), 2.87-2.95 (m, 1H), 2.76-2.84 (m, 2H), 2. 25 (s, 3H), 2.20-2.23 (m, 1H), 1.95-2.00 (m, 1H).
ピーク1: LCMS (ESI): [M+H] 379. 1HNMR: (500 MHz, メタノール-d4) δ 7.20 (s, 1H), 6.96-6.98 (m, 1H), 6.88-6.90 (m, 1H), 6.70-6.71 (m, 1H), 3.83 (s, 3H), 3.77(s, 2H), 2.92-2.96 (m, 2H), 2.76-2.79 (m, 3H), 2.61-2.65 (m, 2H), 2.18 (s, 3H), 2.17-2.18 (m, 1H), 1.82-1.87 (m, 1H).
ピーク2: LCMS (ESI): [M+H] 379. 1HNMR: (500 MHz, メタノール-d4) δ 7.22 (s, 1H), 6.91-6.99 (m, 2H), 6.72-6.75 (m, 1H), 3.88 (s, 3H), 3.71 (s, 2H), 3.10-3.13 (m, 2H), 2.83-2.96 (m, 3H), 2.72-2.74 (m, 2H), 2.25-2.35 (m, 1H), 2.19 (s, 3H), 1.98-2.03 (m, 1H).
ピーク1: LCMS (ESI): [M+H] 346. 1HNMR: (500 MHz, CDCl3) δ 10.61 (br s, 1H), 8.39 (d, J=5.0 Hz, 1H), 7.18 (s, 1H), 7.00 (s, 1H), 6.94 (d, J=5.0 Hz, 1H), 3.66 (s, 2H), 2.96-3.05 (m, 1H), 2. 83-2.85 (m, 1H), 2.78-2.81 (m, 3H), 3.66-2.67 (m, 2H), 2.65 (s, 3H), 2.52 (s, 3H), 2.18-2.29 (m, 1H), 1.96-1.98 (m, 1H).
ピーク2: LCMS (ESI): [M+H] 346. 1HNMR: (500 MHz, CDCl3) δ 10.95 (s, 1H), 8.38 (d, J=5.0 Hz, 1H), 7.18 (s, 1H), 7.00 (s, 1H), 6.94 (d, J=5.0 Hz, 1H), 3.66 (s, 2H), 2.96-3.05 (m, 1H), 2.83-2.85 (m, 1H), 2.78-2.81 (m, 3H), 3.66-2.67 (m, 2H), 2.65 (s, 3H), 2.52 (s, 3H), 2.18-2.29 (m, 1H), 1.95-1.98 (m, 1H).
ピーク1: LCMS (ESI): [M+H] 376. 1HNMR: (500 MHz, メタノール-d4) δ 8.94 (d, J = 5.2 Hz, 1H), 7.15 (s, 1H), 6.78 (d, J = 4.8 Hz, 1H), 6.61 (s, 1H), 3.85 (s, 3H), 3.55-3.66 (s, 2H), 3.06-3.08 (m, 1H), 2.84-2.85 (m, 1H), 2.81-2.83 (m, 1H), 2.40-2.60 (m, 8H), 2.19 (s, 3H), 1.99-2.02 (m, 1H).
ピーク2: LCMS (ESI): [M+H] 376. 1HNMR: (500 MHz, メタノール-d4) δ 7.95 (d, J = 5.6 Hz, 1H), 7.15 (s, 1H), 6.80 (d, J = 5.2 Hz, 1H), 6.61 (s, 1H), 3.85 (s, 3H), 3.56-3.69 (m, 2H), 3.07-3.09 (m, 1H), 2.85-2.89 (m, 1H), 2.69-2.72 (m, 1H), 2.44-2.60 (m, 8H), 2.19 (s, 3H), 1.99-2.02 (m, 1H).
ピーク1: LCMS (ESI): [M+H] 346. 1HNMR: (500 MHz, メタノール-d4) δ 8.80 (s, 1H), 8.51-8.52 (m, 1H), 7.96 (d, J = 8.5 Hz, 1H), 7.60 (s, 1H), 4.38 (s, 2H), 4.05-4.06 (m, 1H), 3.31-3.65 (m, 6H), 3.16-3.17 (m, 2H), 2.81 (s, 3H), 2.25 (s, 3H).
ピーク2: LCMS (ESI): [M+H] 346. 1HNMR: (500 MHz, メタノール-d4) δ 8.83 (s, 1H), 8.55 (d, J = 8.5 Hz, 1H), 7.96 (d, J = 8.5 Hz, 1H), 7.73 (s, 1H), 4.61 (s, 2H), 4.19-4.18 (m, 1H), 3.66-3.69 (m, 3H), 3.38-3.52 (m, 5H), 2.81 (s, 3H), 2.26 (s, 3H).
ピーク1: LCMS (ESI): [M+H] 380. 1HNMR: (400 MHz, メタノール-d4) δ 7.80 (d, J = 5.2 Hz, 1H), 7.22 (s, 1H), 6.83 (t, J = 4.8 Hz, 1H), 3.96 (s, 3H), 3.69-3.72 (m, 2H), 3.04-3.08 (m, 1H), 2.95-2.98 (m, 1H), 2.75-2.84 (m, 5H), 2.20 (s, 3H), 2.14-2.19 (m, 1H), 1.91-1.96 (m, 1H).
ピーク2: LCMS (ESI): [M+H] 380. 1HNMR: (400 MHz, メタノール-d4) δ 7.86 (d, J = 4.8 Hz, 1H), 7.24 (s, 1H), 6.86 (t, J = 4.8 Hz, 1H), 3.98 (s, 3H), 3.73-3.81 (m, 2H), 3.46-3.47 (m, 1H), 3.25-3.26 (m, 1H), 3.07-3.10 (m, 1H), 2.93-2.97 (m, 4H), 2.24-2.38 (m, 1H), 2.21-2.23 (m, 1H), 2.20 (s, 3H).
組換え完全長ヒトOGA酵素はOrigeneから購入した。4-MUGlCNAc基質はSigmaから購入した。その他の試薬はすべてSigmaまたはFisherから購入した。アッセイ緩衝液は、McIlvaine緩衝系、pH6.4(0.2M Na2HPO4を0.1Mクエン酸と混合)及び0.01%BSAからなる。反応物は、1nM OGA、100μM 4-MUGlcNAc(Km)、及び最終容量10μlの化合物からなる。反応物を室温で90分間インキュベートし、40μlの3Mグリシン、pH10でクエンチし、Perkin Elmer Envisionプレートリーダーで読み取った(Ex:355nm/Em:460nm)。化合物は、4倍希釈で20μMから開始する10ポイントの用量反応で試験した。データは、GraphPad Prismを使用して、可変勾配の4パラメータフィッティングを使用してフィッティングした。
Claims (30)
- 以下の構造式によって表される化合物:
Arが、任意置換の5~10員アリールまたは任意置換の5~10員ヘテロアリールであり、Arが、mとpの合計が1である場合、1~4個の窒素原子を有する9員二環式ヘテロアリールではなく;
Wが、Oまたは-NRdであり;
Xが、-CR2R2、-(CR2R2)2、-(CR2R2)O-または-O(CR2R2)-であり;
Y1及びY2が、それぞれCRcまたはNであり、Y1またはY2の少なくとも一方がNであり;
Zが、-CR2R2、-C(=O)、-(CR2R2)2、または-CH2C(=O)であり;
Rcが、-H、ハロ、-C1-C4アルキル、または-C1-C4ハロアルキルであり、
Rdが、-H、C1-C4アルキル、C1-C4ハロアルキル、または-C(=O)C1-C4アルキルであり;
mが、1または2であり;
mとpの合計が3でない限り、pが0または1であり;
nが、0または1~9の整数であり;
nが0以外である場合、R1が、それぞれ独立して、ハロ、-C1-C4アルキル、-C1-C4ハロアルキル、または-C1-C4アルコキシであり;
R2が、それぞれ独立して、-H、ハロ、-C1-C4アルキル、-C1-C4ハロアルキル、-C3-C10シクロアルキル、または-C3-C10ハロシクロアルキルであり;
あるいは、2つのR2が、それらが結合している炭素原子と一緒になって、-C3-C10シクロアルキルを形成し;
R3が、-Hまたは-C1-C4アルキルであり;そして、
R4が、-H、-C1-C4アルキル、-C1-C4ハロアルキル、または-C3-C6シクロアルキルであり;
あるいは、R3及びR4が、それらの介在原子と一緒になって、任意置換の5~7員ヘテロシクリルを形成する、
前記化合物、またはその薬学的に許容される塩。 - 式中、Arが、任意置換の5員または6員単環式ヘテロアリールである、請求項1~14のいずれか一項に記載の化合物。
- 式中、Arが、1つ以上の窒素原子を含む、任意置換の6員単環式ヘテロアリールである、請求項1~15のいずれか一項に記載の化合物。
- 式中、Arが、任意置換のピリジニル、任意置換のピリミジニル、または任意置換のピラジニルである、請求項1~16のいずれか一項に記載の化合物またはその薬学的に許容される塩。
- 式中、Arが、C1-C4アルキル、C1-C4ハロアルキル、C3-C6シクロアルキル、C3-C6ヘテロシクリル、ハロ、-CN、-NO2、-ORz、-NRxRy、-S(O)iRx、-NRxS(O)iRy、-S(O)iNRxRy、-C(=O)ORx、-OC(=O)ORx、-C(=S)ORy、-O(C=S)Rx、-C(=O)NRxRy、-NRxC(=O)Ry、-C(=S)NRxRy、-NRxC(=S)Ry、-NRx(C=O)ORy、-O(C=O)NRxRy、-NRx(C=S)ORy、-O(C=S)NRxRy、-NRx(C=O)NRxRy、-NRx(C=S)NRxRy、-C(=S)Rx、-C(=O)Rx、フェニル及び単環式ヘテロアリールから選択される1つ以上の基で任意に置換され;
式中、
Ar上の前記C1-C4アルキル基置換基が、-CN、-NO2、-ORz、-NRxRy、-S(O)iRx、-NRxS(O)iRy、-S(O)iNRxRy、-C(=O)ORx、-OC(=O)ORx、-C(=S)ORx、-O(C=S)Rx、-C(=O)NRxRy、-NRxC(=O)Ry、-C(=S)NRxRy-NRxC(=S)Ry、-NRx(C=O)ORy、-O(C=O)NRxRy、-NRx(C=S)ORy、-O(C=S)NRxRy、-NRx(C=O)NRxRy、-NRx(C=S)NRxRy、-C(=S)Rx、及び-C(=O)Ry、C3-C6シクロアルキル(-CH3、ハロメチル、ハロ、メトキシ及びハロメトキシから選択される1つ以上の基で任意に置換される)、単環式ヘテロアリール(-CH3、ハロメチル、ハロ、メトキシまたはハロメトキシから選択される1つ以上の基で任意に置換される)及びフェニル(-CH3、ハロメチル、ハロ、メトキシ及びハロメトキシから選択される1つ以上の基で任意に置換される)で任意に置換され;
Ar上の前記C3-C6シクロアルキル、C3-C6ヘテロシクリル、フェニル及び単環式ヘテロアリール基置換基が、任意選択で、かつ独立して、C1-C4アルキル、C1-C4ハロアルキル、ハロ、-CN、-NO2、-ORz、-NRxRy、-S(O)iRx、-NRxS(O)iRy、-S(O)iNRxRy、-C(=O)ORx、-OC(=O)ORx、-C(=S)ORx、-O(C=S)Ry、-C(=O)NRxRy、-NRxC(=O)Ry、-C(=S)NRxRy、-NRxC(=S)Ry、-NRx(C=O)ORy、-O(C=O)NRxRy、-NRx(C=S)ORy、-O(C=S)NRxRy、-NRx(C=O)NRxRy、-NRx(C=S)NRxRy、-C(=S)Rx、及び-C(=O)Rxで置換され;
各Rx及び各Ryが、独立して、-H、C1-C4アルキル、またはC3-C8シクロアルキルであり;RxまたはRyで表される前記C1-C4アルキルまたはC3-C8シクロアルキルが、ハロ、ヒドロキシル、C3-C6シクロアルキル及びフェニル(-CH3、ハロメチル、ハロ、メトキシまたはハロメトキシから選択される1つ以上の基で任意に置換される)から選択される1つ以上の置換基で任意に置換され;
Rzが、-H、C1-C4アルキル、C1-C4アルコキシ、C3-C8シクロアルキル、またはC3-C8ヘテロシクリルであり;Rzで表される前記C1-C4アルキルまたはC3-C8シクロアルキル基が、-CN、ハロ、ヒドロキシル、C1-C4アルキル、C1-C4アルコキシ、C3-C6シクロアルキル、及びフェニル(-CH3、ハロメチル、ハロ、メトキシ及びハロメトキシから選択される1つ以上の基で任意に置換される)から選択される1つ以上の置換基で任意に置換され;そして
iが、0、1、または2である、
請求項1~19のいずれか一項に記載の化合物またはその薬学的に許容される塩。 - 式中、Arが、C1-C4アルキル、C1-C4ハロアルキル、ハロ、-CN、-ORz、及び-NRxRyから選択される1つ以上の基で任意に置換される、請求項1~20のいずれか一項に記載の化合物またはその薬学的に許容される塩。
- 式中、Arが、C1-C4アルキル、C1-C4ハロアルキル、-F、-Cl、-CN、及び-ORzから選択される1つ以上の基で任意に置換され、Rzが、1つ以上のハロ基で任意に置換されたC1-C4アルキルである、請求項1~21のいずれか一項に記載の化合物またはその薬学的に許容される塩。
- 式中、Arが、-CH3、-CF3、-CHF2、-F、-OCH3、-OCHF2、-OCH2CH3、-OCH(CH3)2、及び-OCH2CF3から選択される1つ以上の基で任意に置換される、請求項1~22のいずれか一項に記載の化合物またはその薬学的に許容される塩。
- 請求項1~23のいずれか一項に記載の化合物またはその薬学的に許容される塩と、薬学的に許容される担体または希釈剤とを含む医薬組成物。
- 神経変性疾患、タウオパチー、糖尿病、がん及びストレスから選択される疾患または病態を有する対象の治療方法であって、請求項1~23のいずれか一項に記載の有効量の化合物または請求項24に記載の有効量の医薬組成物を前記対象に投与することを含む、前記治療方法。
- 前記疾患または病態が、急性虚血性脳卒中(AIS)、アルツハイマー病、認知症、筋萎縮性側索硬化症(ALS)、認知障害を伴う筋萎縮性側索硬化症(ALSci)、嗜銀顆粒性認知症、Bluit病、皮質基底核変性症(CBP)、ボクサー認知症、石灰化を伴うびまん性神経原線維変化病、ダウン症候群、てんかん、家族性英国型認知症、家族性デンマーク型認知症、17番染色体に連鎖しパーキンソニズムを伴う前頭側頭型認知症(FTDP-17)、ゲルストマン・シュトロイスラー・シャインカー病、グアドループ型パーキンソニズム、ハラーホルデン・スパッツ病(脳内鉄蓄積を伴う神経変性症1型)、虚血性脳卒中、軽度認知障害(MCI)、多系統萎縮症、筋緊張性ジストロフィー、ニーマン・ピック病(C型)、淡蒼球・脳橋・黒質変性症、グアム型パーキンソニズム-認知症症候群、ピック病(PiD)、脳炎後パーキンソニズム(PEP)、プリオン病(クロイツフェルト・ヤコブ病(GJD)を含む)、バリアント型クロイツフェルト・ヤコブ病(vCJD)、致死性家族性不眠症、クールー病、進行性超皮質性グリオーシス、進行性核上性麻痺(PSP)、スティール・リチャードソン・オルゼウスキー症候群、亜急性硬化性全脳炎、神経原線維変化型認知症、ハンチントン病、及びパーキンソン病から選択される、請求項25に記載の方法。
- 前記疾患または病態が、急性虚血性脳卒中(AIS)、アルツハイマー病、認知症、筋萎縮性側索硬化症(ALS)、認知障害を伴う筋萎縮性側索硬化症(ALSci)、嗜銀顆粒性認知症、てんかん、虚血性脳卒中、軽度認知障害(MCI)、ハンチントン病、及びパーキンソン病から選択される、請求項25及び26のいずれか一項に記載の方法。
- 前記疾患または病態がアルツハイマー病である、請求項25~27のいずれか一項に記載の方法。
- それを必要とする対象におけるO-GlcNAcaseの阻害方法であって:
請求項1~23のいずれか一項に記載の有効量の化合物または請求項24に記載の有効量の医薬組成物を前記対象に投与することを含む、前記阻害方法。 - 脳におけるタウの過剰リン酸化を特徴とする疾患または病態の治療方法であって、請求項1~23のいずれか一項に記載の有効量の化合物または請求項24に記載の有効量の医薬組成物を前記対象に投与することを含む、前記治療方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862775558P | 2018-12-05 | 2018-12-05 | |
US62/775,558 | 2018-12-05 | ||
PCT/US2019/064514 WO2020117961A1 (en) | 2018-12-05 | 2019-12-04 | Morpholinyl, piperazinyl, oxazepanyl and diazepanyl o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022510430A true JP2022510430A (ja) | 2022-01-26 |
JPWO2020117961A5 JPWO2020117961A5 (ja) | 2022-12-12 |
Family
ID=69006035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021531906A Pending JP2022510430A (ja) | 2018-12-05 | 2019-12-04 | モルホリニル、ピペラジニル、オキサゼパニル及びジアゼパニルo-糖タンパク質-2-アセトアミド-2-デオキシ-3-d-グルコピラノシダーゼ阻害剤 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220017506A1 (ja) |
EP (2) | EP4327814A3 (ja) |
JP (1) | JP2022510430A (ja) |
AR (1) | AR117252A1 (ja) |
ES (1) | ES2968733T3 (ja) |
MA (1) | MA54384A (ja) |
TW (1) | TW202039482A (ja) |
UY (1) | UY38498A (ja) |
WO (1) | WO2020117961A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102533471B1 (ko) * | 2020-11-23 | 2023-05-19 | (주) 메디프론디비티 | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
US9206128B2 (en) | 2011-11-18 | 2015-12-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP2812001B1 (en) | 2012-02-10 | 2017-06-14 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
KR102219441B1 (ko) | 2013-02-11 | 2021-02-23 | 콘스텔레이션 파마슈티칼스, 인크. | 메틸 변형 효소 조절제, 이의 조성물 및 용도 |
WO2014151142A1 (en) | 2013-03-15 | 2014-09-25 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2015023915A1 (en) | 2013-08-15 | 2015-02-19 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
CN110300752A (zh) * | 2016-12-16 | 2019-10-01 | 詹森药业有限公司 | 单环oga抑制剂化合物 |
MA47576A (fr) * | 2016-12-16 | 2020-01-01 | Janssen Pharmaceutica Nv | Composés inhibiteurs d'oga bicyclique |
AR110747A1 (es) | 2017-01-27 | 2019-05-02 | Lilly Co Eli | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo |
-
2019
- 2019-12-04 TW TW108144351A patent/TW202039482A/zh unknown
- 2019-12-04 EP EP23199729.7A patent/EP4327814A3/en active Pending
- 2019-12-04 AR ARP190103550A patent/AR117252A1/es unknown
- 2019-12-04 JP JP2021531906A patent/JP2022510430A/ja active Pending
- 2019-12-04 WO PCT/US2019/064514 patent/WO2020117961A1/en unknown
- 2019-12-04 UY UY0001038498A patent/UY38498A/es unknown
- 2019-12-04 ES ES19828102T patent/ES2968733T3/es active Active
- 2019-12-04 US US17/311,232 patent/US20220017506A1/en active Pending
- 2019-12-04 EP EP19828102.4A patent/EP3891146B1/en active Active
- 2019-12-04 MA MA054384A patent/MA54384A/fr unknown
Also Published As
Publication number | Publication date |
---|---|
EP4327814A3 (en) | 2024-04-24 |
WO2020117961A1 (en) | 2020-06-11 |
EP3891146B1 (en) | 2023-09-27 |
AR117252A1 (es) | 2021-07-21 |
EP3891146A1 (en) | 2021-10-13 |
UY38498A (es) | 2020-07-31 |
TW202039482A (zh) | 2020-11-01 |
US20220017506A1 (en) | 2022-01-20 |
ES2968733T3 (es) | 2024-05-13 |
EP4327814A2 (en) | 2024-02-28 |
MA54384A (fr) | 2021-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11040955B2 (en) | Inhibitors of (alpha-v)(beta-6) integrin | |
JP7453916B2 (ja) | O-糖タンパク質-2-アセトアミド-2-デオキシ-3-d-グリコピラノシダーゼ阻害剤 | |
US20100113502A1 (en) | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | |
US10167281B2 (en) | Substituted thiazole or oxazole P2X7 receptor antagonists | |
US20110105459A1 (en) | Azetidines and cyclobutanes as histamine h3 receptor antagonists | |
CN114845711A (zh) | Raf激酶的抑制剂 | |
US20230212139A1 (en) | 2-azaspiro[3.4]octane derivatives as m4 agonists | |
CN109476653B (zh) | 类视黄醇相关孤儿受体γ的杂芳族调节剂 | |
JP2022510430A (ja) | モルホリニル、ピペラジニル、オキサゼパニル及びジアゼパニルo-糖タンパク質-2-アセトアミド-2-デオキシ-3-d-グルコピラノシダーゼ阻害剤 | |
JP2022551853A (ja) | M4作動薬としての5-オキサ-2-アザスピロ[3.4]オクタン誘導体 | |
AU2017332232A1 (en) | 6-membered cyclic amines or lactames substituted with urea and phenyl | |
US8912176B2 (en) | Azetidines as histamine H3 receptor antagonists | |
US11459324B2 (en) | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors | |
WO2020185593A1 (en) | Azetidinyl 0-glyc0pr0tein-2-acetamid0-2-deoxy-3-d-gluc0pyran0sidase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221202 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221202 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240319 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240612 |